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Abstract 
 
Ideally, clinical guidelines would be informed by well-designed randomized experiments. 
However, it is generally not possible to conduct a randomized trial for every clinically relevant 
decision. Decision makers therefore often have to rely on observational data. Guidelines that 
rely on observational data due to the absence of randomized trials benefit when the analysis 
mimics the analysis of a hypothetical target trial. This can be achieved by explicitly formulating 
the protocol of the target trial, and thoroughly discussing the feasibility of the conditions that 
must be met in order to validly emulate the target trial using observational data.  
 
In chapter one, we discuss the emulation of trials that compare the effects of different timing 
strategies, that is, strategies that vary the frequency of delivery of a medical intervention or 
procedures, and provide an application to surveillance for colorectal cancer. In chapter two, we 
discuss a study design that attempts to avoid bias by comparing initiators of the treatment of 
interest with initiators of an “active comparator” that is believed to be inactive for the 
outcome, in order to emulate a randomized trial that compares the treatment of interest with 
an inactive comparator. In chapter three, we describe a new method that combines 
randomized trial data and external information to emulate a different target trial. We apply this 
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method to a randomized trial of postmenopausal hormone therapy in order to emulate a trial 
of a joint intervention on hormone therapy and statin therapy. 
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If the causal effect is not identified 
I desire to believe that the causal effect is not identified 
Let me not become attached to beliefs I may not want
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Methods to estimate the comparative effectiveness of clinical strategies 
that administer the same intervention at different times 
 
 
Anders Huitfeldt, Mette Kalager, James M. Robins, Geir Hoff, Miguel A. Hernán 
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Abstract 
Clinical guidelines that rely on observational data due to the absence of data from randomized 
trials benefit when the observational data or its analysis emulates trial data or its analysis. In this 
paper, we review a methodology for emulating trials that compare the effects of different 
timing strategies, that is, strategies that vary the frequency of delivery of a medical intervention 
or procedure. We review trial emulation for comparing (i) single applications of the procedure 
at different times, (ii) fixed schedules of application, and (iii) schedules adapted to the evolving 
clinical characteristics of the patients. For illustration, we describe an application in which we 
estimate the effect of surveillance colonoscopies in patients who had an adenoma detected 
during the NORCCAP trial.  
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1.    Introduction 
Clinical decisions are increasingly reliant on guidelines, but clinical guidelines are only as good 
as the available evidence on the comparative effectiveness of interventions.1 Ideally, such 
evidence would come from randomized controlled trials. When a randomized trial is not 
available, it may be possible to emulate it using observational data.2 This approach requires 
appropriate confounding adjustment, avoidance of selection bias in the definition of the 
groups to be compared, and formulation of a research question that is relevant for decision 
makers.  
 
Prior explicit attempts to emulate trials using observational data have studied, for example, 
postmenopausal hormone therapy,3 statins,4 epoetin,5 and antiretroviral therapy.6, Here we 
review the emulation of trials to compare strategies that differ in the timing of the intervention 
of interest. As an example, we will consider post-polypectomy surveillance by colonoscopy. 
During this procedure, adenomas (benign tumors of the colon)7 are detected and removed. 
Most adenomas will not develop into colorectal cancer, but most cancers arise from 
adenomas.8 In patients with removed adenomas, surveillance colonoscopies are recommended 
to detect and remove future adenomas before they become malignant. The optimal interval 
between colonoscopies is not known. Current guidelines both in the US9 and the EU10 are 
mostly based on expert opinion due to the scarcity of available evidence. 
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Besides reviewing a methodology to emulate trials for the comparison of strategies that 
administer the same intervention at different times, we also review a classification of these 
strategies. First, we consider point interventions to study the effectiveness of a single 
application of the treatment. Second, we consider sustained interventions to study the 
effectiveness of a fixed treatment schedule (e.g., colonoscopy at 3 years after the initial 
procedure). Third, we consider sustained interventions to study the effectiveness of a 
personalized schedule of treatment (e.g., colonoscopy every year if the most recent procedure 
detected large adenomas, otherwise every 3 years). To fix ideas, we review the methodology in 
the context of its implementation to a cohort of Norwegian individuals. We start by describing 
this cohort. 
 
2.   Data  
The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study was a randomized 
clinical trial of once-only sigmoidoscopy screening versus no sigmoidoscopy, conducted in 
Oslo and Telemark counties in Norway between 1999 and 2001. Our analysis includes 
participants in the sigmoidoscopy arm in whom at least one adenoma was detected (n=2190). 
As part of the trial, endoscopies were conducted in these individuals until the bowel was free 
from adenomas. We excluded patients with history of serious gastrointestinal disease, known 
genetic predisposition to colorectal cancer, and cancer detected as a result of screening in 
NORCCAP.  
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In addition to the available data (age, sex, county, smoking, family history of colorectal cancer, 
and findings at NORCCAP colonoscopies), we conducted a manual chart review at all hospitals 
in Oslo and Telemark—guided by claims data from the governmental single-payer agency 
HELFO—to collect data on the date, findings (e.g., size and type of adenomas) and indication 
of all subsequent colonoscopies and sigmoidoscopies. Of the post-screening endoscopies, 
64% were for surveillance purposes (3% sigmoidoscopies and 61% colonoscopies), 30% were 
clinically indicated because of symptoms (27% colonoscopies, 3% sigmoidoscopies), and 6% 
were due to a recent incomplete endoscopy (4% colonoscopies, 2% sigmoidoscopies).  
 
Our outcome of interest was incidence of colorectal cancer. For many surveillance 
interventions, the use of cancer incidence as an outcome is questionable because of potential 
lead time bias:11 cancer cases will be detected earlier in patients with more intensive 
surveillance, which will make surveillance appear less beneficial. In this case, however, the use 
of the outcome cancer incidence is justified because most of the beneficial effect of 
surveillance colonoscopy seems to be due to removing adenomas before they become 
malignant12, with only a small component of the effect due to earlier detection of prevalent 
cancer. Death from colorectal cancer could not be studied as an outcome because there were 
too few cases.  
 
We refer to the date of the last NORCCAP colonoscopy as time of “first eligibility” for our 
analyses. For each individual, follow-up ends at colorectal cancer, death, sigmoidoscopy, 
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emigration, or December 2011, whichever occurred first. Because we are trying to estimate the 
effects of post-baseline colonoscopies, which were not randomly assigned to the trial 
participants, ours is an analysis of observational data. The flow chart in Figure 1.1 describes the 
enrollment of participants in our study. Table 1.1 displays the characteristics of the eligible 
individuals.  
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Figure 1.1: Flowchart of selection of the 2190 eligible individuals from the intervention arm of 
the NORCCAP trial 
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Table 1.1: Characteristic of 2190 eligible individuals from the intervention arm of the 
NORCCAP trial 
 
Number of men 1322 (60%) 
Average (SD) age at first eligibility, years 57.2 (3.8) 
Median (IQR) duration of follow-up, 
months 
134 (126-143) 
Incident cases of colorectal cancer 21 
 detected at surveillance colonoscopy 1 
Deaths 187 
 from colorectal cancer 5 
Number of colonoscopies during follow-
up 
819 
Number of sigmoidoscopies 75 
Number of people with at least one 
colonoscopy after first eligibility 
 
577 
Number of people whose first follow-up 
colonoscopy was for surveillance  
 
395 
Median (IQR) time to first colonoscopy, 
months 
68 (51-91) 
Number of colonoscopies per individual   
0  1613 (74%) 
1 389 (18%) 
2 140 (6%) 
3+ 48 (2%) 
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3.   Three hypothetical randomized trials 
The design of any trial is determined by the causal question of interest, which in turn is 
determined by the population, the strategies being compared, and the outcome of interest to 
the decision makers.13 For surveillance tests, the strategies are defined by the timing of the 
test. Some strategies involve a point intervention at baseline, whereas other strategies involve 
interventions that are sustained over time according to either a fixed schedule (e.g., do not 
perform a colonoscopy for five years after baseline, then perform a colonoscopy at the end of 
year 5) or a schedule that depends on each individual’s time-evolving clinical characteristics 
(i.e., schedule the time of every colonoscopy according to the findings at the previous 
colonoscopy). We refer to sustained strategies with a fixed schedule as static and to those with 
a subject-specific schedule as dynamic. 
 
Here we review 3 types of hypothetical trials that compare static and dynamic strategies and 
therefore address different questions regarding the effectiveness of surveillance colonoscopy. 
In all trials, eligible individuals are followed until death, loss to follow-up (i.e., emigration out of 
Norway), sigmoidoscopy, occurrence of the outcome (here, diagnosis of colorectal cancer), or 
Dec 31st 2011, whichever occurred earlier. In all trials, individuals receive a colonoscopy 
whenever it is clinically indicated (e.g., due to symptoms) but a surveillance colonoscopy only 
according to the trial protocol. A graphical representation of each trial is shown in Figure 1.2. 
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Trial type #1: Point interventions assigned at a fixed time after first eligibility 
 
Individuals who survived 36 months since first eligibility are randomized to either 1) immediate 
surveillance colonoscopy, or 2) no surveillance colonoscopy. Additional eligibility criteria are no 
colorectal cancer, colonoscopy, or sigmoidoscopy during the 36 months before randomization. 
Individuals who reach age 70 or develop any invasive non-colorectal cancer before baseline 
also become ineligible (other comorbidities might be added to the exclusion criteria). For each 
individual, follow-up starts at the time of randomization, i.e., baseline is 36 months after first 
eligibility.  
 
More generally, one can consider trials in which baseline is month z, where z ranges between 
36 and 84. The effect estimates from these trials will only apply to survivors without symptoms 
or cancer by z months after first eligibility. These trials will help determine the effect of 
undergoing a colonoscopy among the survivors, but it does not directly inform the decision of 
when to undergo the colonoscopy. The next trial does so.  
 
Trial type #2: Sustained static strategies assigned at first eligibility 
Baseline is the time of first eligibility. Individuals are randomized to either 1) surveillance 
colonoscopy 36 months after baseline, or 2) surveillance colonoscopy 84 months after baseline. 
Individuals in both arms who reach age 70 or develop malignancies other than colorectal 
cancer may have surveillance colonoscopies at any time as determined by their physician. More 
generally, one can consider additional arms in which 36 is replaced by any value x between 36 
11	  
	  
and 84. We could also consider similar trials in which baseline is any month after first eligibility. 
For example, one could consider a trial in which individuals who have survived 36 months after 
first eligibility are randomized to either 1) immediate surveillance colonoscopy, or 2) 
surveillance colonoscopy at month 84 after first eligibility (48 months after baseline at 36 
months). We will only consider trials with baseline at first eligibility.  
 
Both trials type #1 and #2 compare fixed surveillance schedules, but they address different 
questions. Trial #1 helps individuals who have survived z months after adenoma removal 
decide whether they should undergo a surveillance colonoscopy at that time. Trial #2 helps 
individuals who just had their adenomas removed decide how long they should wait before 
having a surveillance colonoscopy (if they plan to have only one surveillance colonoscopy). 
Neither trial type considers strategies that assign different surveillance schedules to different 
individuals (i.e., dynamic strategies). The next trial type does so. 
 
Trial type #3: Sustained dynamic strategies assigned at first eligibility 
Individuals at first eligibility are randomized to either 1) receive surveillance colonoscopies 
according to the following rules: 
 
   First surveillance colonoscopy at 36 months if the adenomas detected at baseline 
sigmoidoscopy were low risk (1 or 2 small adenomas without villous features) and 12 
months earlier (at month 24) otherwise.  
12	  
	  
   Follow-up surveillance colonoscopy 36 months after the previous colonoscopy 
(surveillance or clinical) if low-risk adenomas were detected, 12 months earlier (24 
months after the previous colonoscopy) if high-risk adenomas (more than two, or large, 
or containing villous features) were detected, and 12 months later (48 months) if no 
adenomas were detected. 
 
or 2) surveillance colonoscopies according to similar rules, but where 36 months is replaced by 
84 months. During the follow-up, individuals in both arms of the trial may also receive a 
colonoscopy whenever it is clinically indicated due to symptoms. Individuals who reach age 70 
or develop malignancies other than colorectal cancer after baseline may have surveillance 
colonoscopies at any time as determined by their physician. For each individual, follow-up 
starts at the time of randomization, i.e., baseline is the time of first eligibility.  
 
More generally, one can consider additional arms in which 36 is replaced by x with x ranging 
from 36 to 84, or trials in which the time until the next surveillance colonoscopy is obtained by 
adding or subtracting y (rather than 12) months.  
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Figure 1.2: The three trial types considered in Chapter 1 
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4.   Emulating the design of the hypothetical trials 
In this section we review how to emulate the design of each of the above hypothetical trials by 
setting up a database with the same structure as that of the trial. In the next section, we review 
how to mimic the analysis of the hypothetical trials.  
 
Trial type #1: Point intervention assigned at a fixed time after first eligibility 
We emulated 49 “trials,” one starting at each month z between months 36 and 84 after first 
eligibility. For the “trial” starting in month z, we identified the individuals who met the 
eligibility criteria at baseline, i.e., all individuals with adenomas detected and removed at first 
eligibility who were alive and had not yet had a post-screening colonoscopy/sigmoidoscopy or 
been diagnosed with colorectal cancer by z months of follow-up. For each “trial,” individuals 
were classified into the colonoscopy arm if they received a colonoscopy during month z and 
into the control arm otherwise. 
 
We identified 2028 eligible individuals. On average, each participated in 45 “trials,” of which at 
most 1 was in the colonoscopy arm. The number of eligible individuals who received a 
colonoscopy at baseline ranged between 0 (in several “trials”) and 16 (in “trial” z=61). See 
Appendix Table 1 for details. Unfortunately, all “trials” had zero cancers among the exposed, 
which means the data from NORCCAP cannot be used for a meaningful emulation of Trial type 
#1.  
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Trial type #1 has the advantage of being easy to emulate and analyze when sufficient 
observational data are available. This approach has been used in observational studies to 
estimate the observational analog of the intention-to-treat effect of statin therapy4 and 
postmenopausal hormone therapy.3 Here we will not consider this trial type further. 
 
Trial type #2: Sustained static strategies assigned at first eligibility 
We emulated a randomized trial with 49 arms, in which the participants were assigned at first 
eligibility to colonoscopy at a randomly assigned time ranging from month 36 to 84 after first 
eligibility. Classifying the 2190 eligible individuals into a single arm is not possible because, at 
baseline, each individual’s data are consistent with all 49 arms. To overcome this problem we 
created an expanded dataset with 49 clones of each individual who did not receive a 
colonoscopy at baseline, and assigned each of them to a different arm.14 The 2190 eligible 
subjects contributed 107,309 clones to this “trial.” See Appendix Table 2 for details. 
 
The clones in the expanded dataset were censored at the time their data deviated from the 
strategy to which they were assigned. For example, in arm 84, 12.9% of participants were 
censored for having a surveillance colonoscopy too early (before month 84), 73.5% of 
participants were censored for failing to have a surveillance colonoscopy in time (in month 84), 
and 0.5% were censored for having a sigmoidoscopy. Those who received a colonoscopy for 
clinical reasons or developed malignancies other than colorectal cancer were subsequently 
considered “immune” from censoring.  
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Trial type #3: Sustained dynamic strategies assigned at first eligibility 
 
We emulated a trial with 49 arms, one for each value x in the dynamic strategies defined 
above. The 2190 individuals were classified into the arm that was consistent with their 
observed data. Like in the previous trial, individuals cannot be assigned to a single arm at 
baseline, so we created an expanded dataset with 49 clones of each individual and assigned 
each of them to a different arm. The clones were censored at the time they deviated from the 
strategy to which they were assigned. For example, in arm 84, 11.3% of participants were 
censored for having a surveillance colonoscopy too early, 79.7% of participants for failing to 
have a surveillance colonoscopy in time, and 1.3% for having a sigmoidoscopy. The 2190 
eligible subjects contributed 107,309 clones to this “trial.” See Appendix Table 3 for details.  
 
5.    Emulating the design of hypothetical trials with a grace period 
So far we have implicitly assumed that it is possible to administer a colonoscopy at a precisely 
specified time point, e.g., month 36. However, in many clinical settings, this may not be 
feasible. We may therefore be more interested in emulating trials with a grace period, that is, a 
window of m months during which the patient may undergo colonoscopy. For example, in Trial 
type #2, patients would be assigned to interventions of the form “surveillance colonoscopy 
between x and x+m months after baseline.” Trials with a grace period more accurately reflect 
clinical practice in which administrative delays and patient availability may prevent an 
immediate intervention.  
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Strategies with a grace period are emulated using “clones” as described above, but with 
different criteria for censoring. Suppose we use a grace period of m=6 months. An individual 
who received a surveillance colonoscopy in month 40 now has data consistent with arm 36 
because subjects assigned to this arm are allowed to have a colonoscopy at any time between 
months 36 and 42. Therefore his clones assigned to arms 36 to 40 will not be censored 
whereas his clone assigned to arm 41 will be censored because he received a surveillance 
colonoscopy before the assigned time.  
 
The addition of a grace period requires us to specify the distribution of the interventions during 
the grace period. For example, we might ask whether most colonoscopies are performed 
during the first two months of the grace period, or whether they are more equally distributed 
during the grace period. In our application, we will specify a uniform distribution of 
colonoscopies during the grace period.14 
 
In both Trials #2 and #3 with a 6-month grace period, each of the 2190 eligible individuals in 
the original dataset contributed 49 clones, for a total of 107,310 clones to the expanded 
dataset. In trial #2, the average censoring time ranged between 41.9 months for x=36 to 89.1 
months for x=84. In arm 84, 12.9% of participants were censored for having a surveillance 
colonoscopy too early (before month 84), 71.5% of participants were censored at month 90 for 
failing to have a surveillance colonoscopy in time, 0.1% were censored after month 90 for 
having a second surveillance colonoscopy, and 0.6% were censored for having a 
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sigmoidoscopy. Across the 49 arms, there were 381 incident cases of colorectal cancer in the 
clones, which occurred in 12 unique individuals.  
 
In Trial #3, the average censoring time ranged from 34.2 months for x=36 to 78.1 months for 
x=84. For arm 84, 11.3% of participants were censored for having a surveillance colonoscopy 
too early, 77.6% for failing to have a surveillance colonoscopy in time, and 1.4% for having a 
sigmoidoscopy. In total, there were 254 incident cases of colorectal cancer in 13 unique 
individuals. See Appendix Tables 2 and 3 for details. 
 
6.   Emulating the analysis of the hypothetical trials 
After reviewing how to create observational databases with the same structure as hypothetical 
randomized trials, we review how to use those databases to estimate the cumulative incidence 
curves (or their complement, the survival curves) that would have been observed under each 
strategy if all individuals had fully adhered to their original arm assignment. In a slight abuse of 
notation, we index the strategies by the variable x, which was defined in the previous sections. 
For example, in Trial #2, x = 78 corresponds to the strategy “surveillance colonoscopy between 
78 and 78+6 months after baseline.” 
 
In a true randomized trial with many arms x, we could estimate these curves nonparametrically 
(Kaplan-Meier curves) or parametrically by fitting a pooled logistic model of the form 𝑙𝑜𝑔𝑖𝑡	   Pr 𝑌*+, = 0|𝑌* = 𝐷* = 0, 𝑥 = 𝛼4,* + 𝛼,𝑓 𝑥 	  +	  𝛼7𝑓(𝑥)×𝑡, where t denotes time (in months), 
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Yt is an indicator of colorectal cancer by t, Dt an indicator of death by t, 𝛼4,* is a time-varying 
intercept (estimated, for example, via restricted cubic splines for time with knots at 30, 60, 90 
and 120 months), 𝑓(𝑥) is a function of x (for example, a second degree polynomial), and 
𝑓(𝑥)×𝑡 is a product term to allow the hazard ratio to vary during the follow-up. For example, 
for the first 36 months of follow-up, the hazard is known to be identical under all strategies, but 
it may change after that if colonoscopy has a non-null effect on colorectal cancer incidence. 
We would then calculate the predicted values for each value of x and compute their product in 
order to estimate the survival curves. Pointwise 95% confidence intervals for the curves can be 
obtained via a non-parametric bootstrap. In our emulated trials, however, the above logistic 
model needs to be adjusted by both baseline and post-baseline (time-varying) confounders. 
The procedure then needs to be modified as we now describe.  
 
Adjustment for covariates 
In both trials #2 and #3, we need to adjust for covariates that jointly predict surveillance 
colonoscopy At (and therefore censoring) and subsequent outcome. Some of these variables 
are fixed at the baseline of each trial; others vary during the follow-up. Let L0 represent the 
vector of baseline covariates, which include age at baseline, sex, family history of colorectal 
cancer, history of smoking, and findings at NORCCAP colonoscopies (number of adenomas, 
size, histology and presence of villous elements). Let Lt represent the vector of time-varying 
covariates, which include an indicator for incident non-colorectal malignancies, and a vector of 
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the findings from the most recent colonoscopy (number of adenomas, size of largest adenoma, 
histological grade and presence of villous elements).  
 
To adjust for L0, one could fit the pooled logistic model 𝑙𝑜𝑔𝑖𝑡	   Pr 𝑌*+, = 0|𝑌* = 0	  , 𝑥, 𝐿4 = 𝛼4,* +𝛼,𝑓 𝑥 +	  𝛼7𝑓(𝑥)×𝑡 + 𝛼<𝐿4	  to the expanded dataset of each trial separately. To obtain the 
survival curves under each strategy x, one would then calculate the predicted values for each 
value of x, standardized them by L0 and compute their product. However, the time-varying 
covariates Lt cannot be added to the logistic model because these variables may be affected 
by prior treatment10,11 (a colonoscopy may change the findings at future colonoscopies, for 
example by removing adenomas; see Appendix). We therefore need to use IP weighting to 
adjust for Lt. 
 
The subject-specific, time-varying IP weights are 𝑊* = 	   ,> 𝐴@ 𝐴@A,, 𝐿@, 𝑌@ = 𝐷@ = 0*@B4 . 
Informally, the denominator of the weights is each subject’s conditional probability of having, 
at each time t, his or her own surveillance colonoscopy history. We use overbars to denote 
history, i.e., 𝐿* =(L0, L1, L2, …., Lt). 
 
The factors in the denominator of the weights were set to 1 in months following age 70, a non-
surveillance colonoscopy, or the diagnosis of malignancies other than colorectal cancer 
because the individual has a probability 1 of remaining uncensored during those months. The 
factors in the denominator were also set to 1 during the first 9 months after a colonoscopy is 
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received, because no surveillance colonoscopies were performed during this period (only 
colonoscopies due to symptoms or to incompleteness of the preceding colonoscopy). In 
previous applications of IP weighting for strategies with grace periods, the investigators were 
interested only in strategies that were not sustained beyond the initial decision to treat.14 
Therefore, the contributions to the weights were set to 1 for all time periods after treatment 
was first received. 
 
For all other months, we estimate the denominator by fitting a logistic model for the 
conditional probability of receiving a colonoscopy to the original, unexpanded study 
population. We fit the model 
𝑙𝑜𝑔𝑖𝑡	   Pr 𝐴* = 1|𝐴*A,, 𝐿* = 𝛽4,* + 𝛽,𝑔(𝐴*A,)𝑃* + 	  𝛽7𝐿4 + 	  𝛽<𝐿*𝑃* 
where 𝛽4,* is a time-varying intercept estimated via restricted cubic splines with knots at 30, 60, 
90, and 120 months, 𝑔(𝐴*A,) is the time since the most recent colonoscopy, and covariate 
history 𝐿*	  is summarized via the time-varying covariates Lt and the baseline variables L0, which 
include age (restricted cubic splines with knots at 50, 55, 60, and 65 years), sex, family history 
of colorectal cancer (yes/no), history of smoking (yes/no), findings at the NORCCAP 
colonoscopies (indicators for 3 or more adenomas, adenoma greater than 10mm, adenoma 
with villous component, and histological grade (1 if high grade dysplasia, 0 otherwise). The 
variables 𝑔 𝐴*A,  and 𝐿*	  are entered to the model only in a product (“interaction”) term with Pt, 
an indicator for prior colonoscopy (1 if the individual had a colonoscopy before t, 0 otherwise), 
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such that the terms are zero in individuals who have not had a previous surveillance 
colonoscopy. 
 
Because the IP weights already adjust for the baseline covariates L0, we did not include them as 
covariates in the outcome model. That is, we fit the weighted pooled logistic model 𝑙𝑜𝑔𝑖𝑡	   Pr 𝑌*+, = 0|𝑌* = 0	  , 𝑥 = 𝛼4,* + 𝛼,𝑓 𝑥 +	  𝛼7𝑓 𝑥 ×𝑡. To check the robustness of our 
estimates to different choices of functional form for time and x, we explored different 
parameterizations of the outcome model, including a quadratic functional form for time, cubic 
terms for x, and additional interaction terms between f(x) and time.  
 
Grace Period 
Because our strategies of interest include grace periods, the above IP weights Wt need to be 
modified.14 Specifically, the numerator of the factors corresponding to months included in the 
grace period need to change to ensure that surveillance colonoscopies will be uniformly 
distributed during the grace period. For trial #2, the numerator of factors corresponding to 
month j of the grace period is replaced by ,F+,A@ with j = 0, 1, …5 when At =1, and replaced by 
FA@F+,A@	  when At = 0. For trial #3, where there can be multiple surveillance colonoscopies, we use 
the same approach during all grace periods. 
	  
Estimates from NORCCAP data 
23	  
	  
Table 1.2 shows the 5- and 10-year risks of colorectal cancer for arms 36 and 84 in Trials #2 and 
#3. For both static and dynamic strategies, earlier surveillance colonoscopy resulted in a lower 
risk. The estimated survival curves for selected arms of trials #2 and #3 are shown in Figure 1.3. 
As expected, the survival curves are essentially identical over the first three years, as the 
strategies are the same during this time period. Results were similar in sensitivity analyses using 
different functional forms for f(x) and time.  
 
Note that, had the dataset included no cancer diagnoses after surveillance colonoscopy, the 
conclusion that delaying colonoscopy increases risk would be foregone. In our dataset, only 
one individual who has a surveillance colonoscopy between months 36 and 84 subsequently 
developed colorectal cancer, and he was censored before getting cancer under most clinically 
relevant strategies. Any changes to the strategies that led to him not being censored, would 
result in substantial changes to the estimates. Therefore our analysis needs to be replicated in 
a larger dataset.  
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Figure 1.3: Estimated survival curves for Trials #2 and #3 
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Table 1.2: Estimated risk of colorectal cancer at 5 and 10 years under selected surveillance 
strategies, intervention arm of the NORCCAP trial  
	  
 Risk, % (95% CI)  
x=36 
Risk, % (95% CI) 
x=84 
Risk difference, % 
(comparing x=36 
with x=84) 
(95% CI) 
Risk ratio  
(comparing x=36 
with x=84)  
(95% CI) 
Static Strategies 
At 5 years 
At 10 years 
  
0.15 (0.03-0.37) 
0.31 (0.05-0.69) 
 
0.30 (0.08-0.59) 
0.63 (0.27-1.14)  
 
-0.15 (-0.31 – 0.00)  
-0.32 (-0.67 – 0.01) 
  
0.47 (0.06-0.87) 
0.49 (0.10-1.01)  
Dynamic Strategies 
At 5 years 
At 10 years 
 
 
0.12 (0.00-0.36) 
0.30 (0.05-0.90) 
 
0.25 (0.01-0.50) 
0.44 (0.17-0.76) 
 
-0.13 (-0.30 – 0.01) 
-0.14 (-0.46 – 0.03) 
 
0.49 (0.03-1.18) 
0.67 (0.10-1.76) 
 
 
 
  
26	  
	  
7.    Conclusions 
After a medical procedure or medication has been shown to be effective, the next question is 
usually how often it should be administered. In this paper, we reviewed an approach that, when 
applied to a sufficiently large and rich dataset, helps decide among various timing strategies. 
Specifically, we outlined the design and analysis of hypothetical randomized trials to compare 
different strategies, and provided a methodology for emulating these trials using observational 
data.  
 
As a motivating example, we compared the effectiveness of different strategies for scheduling 
surveillance colonoscopies in patients with adenomas, a clinical question for which the 
available evidence is sparse.9,15-20 Our analysis suggests that more frequent surveillance 
colonoscopies leads to a greater reduction in colorectal cancer risk; as expected, the analysis 
also suggests that dynamic strategies are more effective than static strategies. However, our 
analysis is more an example of implementation than an attempt at providing definite answers 
to the clinical question because the sample size of our study was small.  
 
The application of the methods outlined in this review allowed us to specify a research 
question that is directly relevant to decision makers interested in timing questions. Though 
these methods allow adjustment for both baseline and time-varying covariates, the possibility 
of unmeasured confounding remains as in any observational study.  
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Active comparators to emulate target trials with inactive comparators 
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Abstract 
Because non-initiators of treatment differ from initiators in terms of unmeasured variables 
including access to healthcare and health-seeking behavior, guidelines for the conduct of 
observational research often recommend using an “active” comparator group consisting of 
people who initiate a treatment other than the medication of interest. In this paper, we discuss 
the conditions under which this approach is valid if the goal is to emulate a trial with an inactive 
comparator. We provide four different conditions under which a target trial in a subpopulation 
can be validly emulated from observational data, using an active comparator that is known or 
believed to be inactive for the outcome of interest. The average treatment effect in the 
population as a whole is not identified, but under certain conditions this approach can be used 
to emulate a trial either in the subset of individuals who were treated with the treatment of 
interest, in the subset of individuals who were treated with the treatment of interest but not 
with the comparator, or in the subset of individuals who were treated with both the treatment 
of interest and the active comparator. We discuss whether the required conditions can be 
expected to hold in pharmacoepidemiologic research, with a particular focus on whether the 
conditions are plausible in situations where the standard analysis fails due to unmeasured 
confounding by access to health care or health seeking behaviors. 
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1.   Introduction 
Randomized trials to evaluate the effectiveness or safety of an active treatment can be 
classified into two groups: trials that compare the treatment of interest with an active treatment 
which is a clinical alternative to the treatment of interest (head-to-head trials), and trials that 
compare the treatment of interest with an inactive comparator such as placebo or usual care 
without treatment. Observational data are often used to try to emulate both types of 
randomized trials. Head-to-head trials may be emulated via comparisons of individuals 
initiating the treatment of interest versus initiating the active comparator. Trials with inactive 
comparators may be emulated via comparisons of individuals initiating versus not initiating the 
active treatment. 
 
While all trial emulations using observational data are subject to bias, emulating trials with 
inactive comparators is especially challenging because people who initiate treatment may be 
different from non-initiators in ways that are difficult to assess: access to healthcare, health-
seeking behaviors, time since and accuracy of the measurement of confounders, outcome and 
comorbidities. As a result, the observational estimates may be biased by unmeasured 
confounding and differential mismeasurement of key variables.1 This bias is of particular 
concern in studies that rely on administrative data.2,3 
 
A proposal to reduce these biases in observational research is the use of active comparators 
even when the goal of the research is to emulate a trial with inactive comparators. To do so, 
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investigators often choose an active comparator that is thought to be inactive for the outcome 
under consideration and therefore, generally, will not be a clinical alternative to the treatment 
of interest. It has been argued that using such active comparators may mitigate bias because 
initiators of the treatment of interest and of the active comparator are expected to have a 
similar health status4 and use of the health care system5, and comparable quality of 
information.  
 
The use of active comparators has been endorsed in several guidelines for the conduct of 
observational research, including the GRACE principles,1 AHRQ’s “Protocol for Observational 
Comparative Effectiveness Research”,2 PCORI’s “Standards for Causal Inference in Analyses of 
Observational Studies”3 and the FDAs “Best practices for conducting and reporting 
pharmacoepidemiologic safety studies”.6 Table 2.1 summarizes several published examples of 
observational studies that used active comparators to emulate trials with inactive comparators. 
 
However, these guidelines do not describe the method in detail. For example, none of these 
documents explicitly differentiate between the use of active comparators to emulate head-to-
head trials or to emulate trials with inactive comparators. In addition, they do not provide a 
precise definition of the causal effect that is to be estimated when active comparators are used, 
and therefore cannot characterize the conditions that are necessary in order to identify this 
causal effect. Finally, the guidelines neither specify whether the treatment group should 
exclude individuals who also take the comparator drug nor whether the analysis should be 
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restricted to individuals with indications for both active treatments. As a result, different 
versions of active comparator approaches exist (see Table 2.1). 
 
In this paper, we consider the possible designs of observational studies that use active 
comparators to emulate trials with inactive comparators. We characterize the causal effect that 
is targeted by each design and the comparability assumptions under which the design-specific 
causal effects are identified from the data. Since we are interested in identification and not 
inference we shall ignore sampling variability by supposing the study population is sufficiently 
large that sampling variability can be ignored.  
 
As a running example, we will consider a target trial whose goal is to compare usual care plus 
initiation of statin therapy (A=1) vs. usual care without initiation of statin therapy (A =0) on the 
5-year risk of coronary heart disease Y (1: yes, 0: no) in some well-defined study population, say 
an insurance or medicare data base. We shall sometimes use “treated” as shorthand for 
“subjects who initiated treatment with statins.” 
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Table 2.1: Examples of observational studies that use active comparators to emulate 
randomized trials with inactive comparators 
	  
Study Treatment group  Comparator group 
 
Outcome 
Glynn et al 
(2001)12 
Initiators of several 
classes of cardiac drugs 
Initiators of glaucoma 
drugs 
Death 
Glynn et al 
(2006)13 
Initiators of lipid-
lowering medications 
Initiators of any other 
medications who do not 
use lipid-lowering 
medications 
Death 
Solomon et al 
(2006)5 
Initiators of 
NSAIDS/Coxibs 
Initiators of 
glaucoma/hypothyroidis
m therapy who do not 
take NSAIDs/Coxibs 
Hospital 
admission for 
myocardial 
infarction or 
stroke 
Schneeweiss et 
al (2007)14 
Initiators of statins who 
do not use glaucoma 
therapy 
Initiators of glaucoma 
therapy who do not use 
statins 
Death 
Setoguchi 
(2007)15  
Initiators of statins who 
do not use glaucoma 
therapy 
Initiators of glaucoma 
therapy who do not use 
statins 
Lung, breast 
and colorectal 
cancer 
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2.   Emulating a trial with inactive comparators in a subset of the study population  
To fix ideas, we first review the counterfactual approach to causal inference. We shall let the 
counterfactuals Ya=1 and Ya=0 denote the outcome of interest Y when treated and not treated 
with statins respectively. We make the consistency assumption that a subject’s observed 
outcome Y is equal to Ya=1 if the subject initiated statin treatment; otherwise Y is equal to Ya=0 .  
 
We first consider two causal effects that are often of interest. The first of these is the average 
treatment effect (ATE) in the entire study population E[Ya=1] - E[Ya=0], ie the difference between 
the 5-year risk of coronary heart disease had everyone undergone usual care plus initiation of 
statin therapy (E[Ya=1]), and the 5-year risk of coronary heart disease had everyone undergone 
usual care alone (E[Ya=0]). To identify the average causal effect in the entire population we need 
to be able to identify both E[Ya=0] and E[Ya=1] from the observed data. If the ATE is identified, 
we are able to emulate a trial comparing initiation of statins with usual care in the entire study 
population.  
 
The second is the average causal effect in the treated population E[Ya=1 |A=1]- E[Ya=0 |A=1] 
which is often referred to as the effect of treatment on the treated (ETT). The ETT compares 
the five-year risk of coronary heart disease under statin therapy and usual care in the subgroup 
of the population who were observed to initiate treatment with statins. Since by consistency 
the average Ya=1 among subjects observed to have A=1 is equal to the mean of Y among these 
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subjects, we have that E[Ya=1 |A=1] is equal to E[Y|A=1] and the ETT is E[Y |A=1]- E[Ya=0 |A=1]. In 
other words, confounding by unmeasured factors is not an issue for E[Ya=1 |A=1] and thus to 
identify the ETT it is sufficient to identify the mean E[Ya=0 |A=1] of Ya=0 from the observed data. 
If the ETT is identified, we will be able to emulate a trial in the subset of the study population 
who initiated statin treatment.  
 
As discussed above, the observational difference in risk of coronary heart disease between 
statin initiators and non-initiators, E[Y|A=1] – E[Y|A=0], may be biased for the ATE contrast 
E[Ya=1] – E[Ya=0] and for the ETT E[Ya=1|A=1] – E[Ya=0 |A=1]. The bias may persist even if the 
observational contrast were computed within levels of the measured confounders L available in 
the data base, i.e., E[Y|A=1, L=l] – E[Y|A=0, L=l], owing to within-stratum confounding by 
unmeasured factors and measurement error. For notational simplicity, in this paper we often 
suppress L=l from the conditioning event, but consider that all observational contrasts are 
calculated in a subset of the population L=l.  
 
3.   Three Designs 
In an attempt to eliminate the bias, we can consider three possible active comparator designs. 
In the following we let B denote the active comparator drug so that subjects with B=1 initiate 
the active comparator and subjects with B=0 do not. Consider subjects who have yet to initiate 
either treatment at some fixed time from start of follow-up divided into 4 groups: Group (1) 
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consists of subjects who initiate A but not B, Group (2) consists of subjects who initiate B but 
not A, Group (3) consists of subjects who initiate both A and B and Group (4) consists of 
subjects who initiate neither A nor B. Note that if A and B are alternative therapies for the same 
illness then it may be that there exist no subjects initiating A and B at once. Since, as discussed 
in the introduction, we are considering the case in which A and B do not treat the same 
condition, we will assume there do exist simultaneous initiators.  
 
In all designs we compare the observed mean of the outcome in some subset of the treated 
with the mean outcome among the untreated subjects who initiate the comparator drug. In 
design 1, we use the mean outcome in all subjects treated with statins. In design 2, we use the 
mean outcome in treated subjects who do not take the comparator drug. In design 3, we use 
the mean outcome in treated subjects who take the comparator drug. Thus we replace the 
usual observational contrast E[Y|A=1] – E[Y|A=0] by one of the following design specific 
observational contrasts: 
 
Design 1: E[Y|A=1] – E[Y|A=0, B=1] 
Design 2: E[Y|A=1, B=0] – E[Y|A=0, B=1] 
Design 3: E[Y|A=1, B=1] – E[Y|A=0, B=1] 
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We next discuss the causal effect targeted by each design. Recall that B is an active treatment 
which is known or thought to be inactive for the outcome Y. In our running example we take B 
to be an active therapy for glaucoma that is inactive for our outcome coronary heart disease. 
The above observational contrasts do not generally identify the ATE, ie average causal effect of 
A=1 versus A=0 in the entire study population, E[Ya=1] – E[Ya=0]. However, under certain 
comparability conditions described below, each of these contrasts identifies the average causal 
effect of A=1 versus A=0 in a particular subset of the treated population that depends on the 
design: Under design 1, it is the entire population treated with treatment A (groups 2 and 3); 
under design 2 it is the subset of treated population who do not initiate treatment B (group 2), 
and under design 3 it is the subset of treated who initiate treatment B (group 3).  Figure 2.1 
illustrates the groups compared and the trials that are emulated by each design.  
 
We now describe the comparability conditions under which each of the above design specific 
observational contrasts identifies these effects. Let pab ≡ E[Ya=0|A=a, B=b]. For example, p01 is 
the mean of Ya=0 among subjects who initiate glaucoma therapy (treatment B) but do not 
initiate statins (treatment A). Consider the four comparability conditions: 
i.   p11=p01 
ii.   p10=p01  
iii.   p10=p01=p11  
iv.   p10=p01=p11 =p00  
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We now show that certain of these conditions identity the subpopulation causal effects 
described earlier.  
 
The effect of A among those initiating A and B 
Condition (i) states that among subjects initiating B, those also initiating treatment A have the 
same mean of Ya=0 as those not initiating A. Under comparability condition (i), the contrast 
E[Y|A=1, B=1] – E[Y|A=0, B=1] of Design 3 identifies the effect of active treatment A=1 versus 
no treatment A=0 among the subset initiating both A and B. In our example, this is the average 
causal effect of statins versus no statins among subjects who initiated both statins and 
glaucoma therapy.  
 
Lemma 1: If p11=p01 then E[Y|A=1, B=1] – E[Y|A=0, B=1]= E[Ya=1-Ya=0|A=1, B=1]. 
Proof: 
E[Y|A=1, B=1]  = E[Ya=1|A=1, B=1]   by consistency 
E[Y|A=0, B=1]  = E[Ya=0|A=0, B=1]   by consistency 
= E[Ya=0|A=1, B=1]   by (i) 
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The effect of A among those treated with A but not B 
Condition (ii) states that subjects initiating B but not A have the same mean of Ya=0 as those 
initiating A but not B. Under condition (ii), the contrast E[Y|A=1, B=0] – E[Y|A=0, B=1] identifies 
the effect of active treatment A=1 versus no treatment A=0 among those initiating A but not B. 
In our example, this effect is the average causal effect of statins versus no statins among 
initiators of statins who did not initiate glaucoma therapy.  
 
Lemma 2: If p10=p01 then E[Y|A=1, B=0] – E[Y|A=0, B=1]= E[Ya=1-Ya=0|A=1, B=0].  
Proof:  
E[Y|A=1, B=0]  = E[Ya=1|A=1, B=0]   by consistency 
E[Y|A=0, B=1]  = E[Ya=0|A=0, B=1]   by consistency 
= E[Ya=0|A=1, B=0]   by (ii) 
Lemma 2 is essentially due to Rosenbaum (2007).7,8 
 
The effect of A among those treated with A 
Under condition (iii), we obtain the above results plus we identify the effect of treatment on the 
entire treated population (A=1). Under this condition, the contrast E[Y|A=1] – E[Y|A=0, B=1] 
identifies the effect of active treatment A=1 versus no treatment A=0 among those who 
initiated A in the observational data. In our example, this is the average causal effect of statins 
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versus no statins among all initiators of statins. As noted earlier, this causal estimand is 
commonly referred to as ETT 
 
Lemma 3: If p10=p01=p11 then not only are the results of Lemma 1 and 2 true but in addition 
E[Y|A=1] – E[Y|A=0, B=1]= E[Ya=1-Ya=0|A=1] 
Proof:  
E[Y|A=1]   = E[Ya=1 | A=1]   by consistency 
E[Y|A=0, B=1]   = E[Ya=0 | A=0, B=1]   by consistency 
= E[Ya=0 | A=1]   by (iii) 
 
It is easy to see that condition (iii) both implies and is implied by conditions (i) and (ii). If the 
even stronger condition (iv) holds, the observational contrast E[Y|A=1] – E[Y|A=0] identifies the 
effect of A in the treated. In other words, if condition (iv) holds we would not need to collect 
data on B to identify the ETT  
 
Lemma 4: If p10=p01=p11 =p00 then E[Y|A=1] – E[Y|A=0] = E[Ya=1-Ya=0|A=1] 
Proof: 
E[Y|A=1]   = E[Ya=1 | A=1]   by consistency 
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E[Y|A=0]   = E[Ya=0 | A=0]   by consistency 
   = E[Ya=0 | A=1]   by (iv)  
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Figure 2.1: Venn diagrams showing the groups compared and the subpopulation to which the 
effect estimates apply 
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4.   The comparability conditions 
 
The results in the previous section depend on comparability conditions (i)-(iv). Since these 
conditions, like other comparability conditions, can be neither empirically verified nor refuted 
we should only adopt those that are plausible a priori. We now discuss the plausibility of these 
conditions.  
 
We begin by showing that unless the comparator B has no direct effect on the outcome of 
interest we could not expect any of the above conditions except possibly (i) to hold. This 
should not be surprising, as the causal null hypothesis for the comparator is essential to the 
intuition behind most active comparator study designs. To proceed we need some further 
definitions. Let Ya,b be the counterfactual representing the joint effect of A and B on Y. The 
counterfactuals Ya discussed earlier are determined by the counterfactuals Ya,b via consistency. 
Specifically, Ya = Ya, b=1 for subjects treated with B (B=1) in the observed data. For subjects with 
B=0 in the data, Ya = Ya, b=0. 
 
By definition, B has no direct effect on Y if Ya = Ya, b=0 = Ya, b=1 for each subject. If B had a direct 
effect, the condition p10=p01 becomes E[Ya=0,b=1|A=0, B=1] = E[Ya=0,b=0|A=1, B=0]. Since the 
counterfactuals Ya=0,b=1 and Ya=0,b=0 would differ, there is no a priori reason to expect the mean of 
Ya=0,b=1 in a subgroup to equals that of Ya=0,b=0 in a second subgroup. As conditions (iii) and (iv) 
hold only if condition (ii) does, they too are implausible if B has a direct effect. Henceforth, we 
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will assume the investigators have chosen a comparator B which has no direct effect on the 
outcome. 
 
Next turn to condition (iv). This condition is implausible because it implies that subjects who 
initiated neither treatment A nor treatment B are comparable to those who did, which as 
discussed in the introduction cannot be assumed, an observation which indeed motivated the 
need for active comparators. We therefore proceed to discuss the weaker conditions (i), (ii) and 
(iii), focusing on describing hypothetical situations where the weaker conditions (i), (ii) or (iii) 
hold but (iv) does not. In such settings, an active comparators design may be required.  
 
Consider two indistinguishable groups of subjects in the population with different means of 
Ya=0, and hence non-comparable. We label these groups G1 and G2. Conditions (i), (ii) and (iii) 
but not (iv) would hold if all G1 members refrain from initiating either A or B, whereas 
comparability condition (iv) holds in G2. Therefore, all subjects who initiated either A or B 
would be in G2 while those who initiated neither would be an indistinguishable mixture of 
groups G1 and G2. As an example, we might suppose all subjects with health seeking behaviors 
were in G2 and those without were in G1. However, since covariates such as health seeking 
behavior are not truly binary, and since sicker individuals will tend seek health care 
preferentially, it is implausible that the division into such groups will ever hold precisely.  
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An alternative way to think about condition (iii) is in terms of a treatment choice model as 
discussed by Rosenbaum using ideas introduced by Tversky and Sattath (1979).11 In these 
models, a subject first decides whether to refrain from all treatment or not, and then decides 
which treatment to take. The probability of refraining from treatment can depend on Ya=0, but 
after having decided to take a treatment the decision about whether to take A, B or both 
cannot further depend on Ya=0. Again, it is implausible that this model would hold exactly.  
 
Such a mechanistic treatment model can also be used to describe a situation where condition 
(ii) but not (iii) would hold. For example, this would occur the subject first decides whether to 
take one, two or no treatments; with the decision depending on Ya=0; and in the event that he 
decides to initiate one treatment proceeds to choose among A and B with a probability that 
does not depend on Ya=0. As discussed by Rosenbaum, this scenario might be plausible if A 
and B were alternative therapies prescribed for the same indication. However, these models 
become implausible when, as in this paper, the indication for treatment with the comparator B 
(e.g., glaucoma therapy) differs from that for active treatment A (statins).  
 
The requirements for condition (i) are less restrictive. This condition would hold if among 
initiators of treatment B, initiators and noninitiators of treatment A are exchangeable with 
respect to the outcome Y, ie if Ya=0 ∐ A | B=1. This condition will be true under the following 
scenario: Suppose that initiators and noninitiators of statins are not exchangeable because of 
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differences in health care access (an unmeasured variable). If all initiators of treatment B have 
access to health care then, in the subset of initiators of B, initiators and noninitiators of A do 
not differ with respect to health care access. Therefore, conditional on prognostic factors other 
than health care access, comparability condition (i) would hold among initiators of B even if 
health care access remains unmeasured. Note in addition that B having a direct effect on Y has 
no bearing on the plausibility of condition (iv)  
 
All conditions in this paper will be violated if there exist unmeasured common causes of A and 
Y other than those that can be controlled by conditioning on B=1. Moreover, conditions (ii), (iii) 
and (iv) will all be violated if there exist unmeasured common causes of B and Y other than 
those that can be controlled by conditioning on A=1. Therefore, to justify the use of designs (2) 
or (3), the investigators will have to control for all indications for treatment A and all indications 
for the active comparator B. If medications A and B have different indications, this will usually 
produce a violation of the necessary positivity condition: Nobody will be treated with statins 
unless they have elevated cholesterol, and nobody will be treated with glaucoma therapy 
unless they have glaucoma. Investigators are therefore required either to limit the analysis to 
those individuals who have indications for both medications, or alternatively make the 
additional assumption that having glaucoma is independent of the outcome (such that it does 
not need to be controlled for). 
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Finally, we want to point out that all independence assumptions in this section are defined in 
terms of counterfactual variables that are specific for each outcome Y under consideration. It is 
often the case that a comparator will be independent of one outcome, but not another.  
 
5.   Using active comparators to reduce misclassification bias 
Besides potentially making the treatment groups more comparable in terms of unobserved 
covariates, the second argument for using active comparators in observational studies is that it 
may protect against a certain form of differential misclassification bias. Specifically, people who 
have not started a drug recently may not have all their comorbidities entered in the database, 
for instance because they have not had a recent physical examination. In observational 
research using health care databases, such individuals are generally considered not to have the 
condition; this phenomenon will therefore usually result in misclassification of the variable 
rather than missing data.  
 
Differential misclassification due to lack of access to healthcare will generally not affect 
measurement of the treatment: People who do not have access to healthcare will correctly be 
recorded as not being treated. In contrast, the outcome Y will often be measured with error for 
reasons related to access to health care.  
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Let Y* be the measured value of the outcome. The active comparators design can be used to 
eliminate differential misclassification of the outcome if condition (4) holds, ie p10=p01=p11 =p00 , 
and Y is measured accurately if the patient has access to health care, such that E[Y* | A=a,B=b] 
= E[Y | A=a,B=b] for all strata except a=0, b=0 where Y is measured with error.  
 
An example of such a situation is as follows: Suppose non-initiators of statins are 
disproportionally more likely to be uninsured than initiators, and uninsured individuals with 
chest pain are less likely to seek medical attention. In such a situation, the non-initiator group 
will be less likely to be diagnosed if they have silent myocardial infarctions and E[Y* | A=0,B=0] 
< E[Y|A=0,B=0]. In such a situation the standard analysis will have a bias that makes treatment 
appear falsely more effective at reducing the incidence. We may hope to eliminate this bias by 
using a comparator group consisting of glaucoma therapy initiators, as glaucoma therapy 
initiators are known to have adequate access to health care and will be diagnosed with the 
same accuracy as statin users if symptoms occur.  
 
This type of bias does not occur when the outcome (e.g., death) is measured accurately in all 
individuals. In this setting, concern about misclassification is not a compelling reason to use an 
active comparator design.  
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It is also possible for the confounders to be misclassified for the same reasons discussed above 
for the outcome. However since doctors can only make treatment decisions based on the 
information that they have available, the measured value of the variable is usually the proximal 
cause of treatment initiation; controlling for the mismeasured version is therefore generally 
preferable to controlling for the true value. For this reason, mismeasurement of confounders 
due to lack of access to healthcare is not a concern for most uses of health care databases.  
 
Finally, in situations where differential misclassification may be eliminated by the use of an 
active comparators design, it is usually the case that a similar objective can be achieved simply 
by restricting the study to individuals who had a certain level of health care utilization prior to 
baseline.  
 
6.   Discussion 
Observational studies that compare two active drugs often have less confounding than studies 
that compare a drug to no treatment. However, these two types of studies estimate different 
effects. We encourage investigators to think closely about what effects they are estimating 
when using “active comparators” to emulate a target trial of treatment versus no treatment. In 
this paper, we have provided the conditions under which such a trial can be validly emulated 
using a comparator group that consists of initiators of an active treatment that is inactive for 
the outcome of interest.  
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We have discussed four different conditions that allow the identification of subtly different 
causal effects. In most settings, condition (i) will be the most plausible one (it holds under a 
standard exchangeability assumption, and it does not rely on the assumption that the 
comparator treatment has no effect on the outcome), but an approach based on condition (i) 
will reduce sample size considerably and will restrict the interpretation of the estimated effect 
to the small subset of the population who share characteristics with those subjects who 
initiated both treatment A and treatment B in the observational data. Conditions (ii), (iii) and (iv) 
will be difficult to justify in most settings. Condition (ii) is weaker than condition (iii), and 
therefore less likely to be violated, but condition (iii) identifies a potentially more relevant 
causal effect.  
 
One potential way to test whether these conditions hold approximately would be to obtain 
observational data containing all relevant covariates including access to health care and health-
seeking behavior, and see whether an analysis that strips the dataset of these variables is able 
to use the methods proposed in this paper to obtain the same results as the standard analysis 
for estimating the causal effect in the corresponding subgroup.  
 
In any design that uses active comparators in observational data, it will be difficult to analyze 
multiple outcomes within the same study. This is because the active comparator has to be 
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chosen specifically in the context of subject-matter knowledge about the relationship between 
the comparator and the outcome under study, and justifications for using an active comparator 
comparator B for one outcome Y do not readily transfer to using the same comparator for a 
different outcome. 
 
In summary, investigators who employ an active comparators design to emulate a trial with 
inactive comparators should exercise caution.  
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CHAPTER 3     
 
 
 
 
Can the results of the WHI E+P trial be explained by differential statin initiation? 
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Abstract: 
In 2002, the Women’s Health Initiative clinical trial was stopped early after it became clear that 
hormone replacement therapy was associated with an increased risk of coronary heart disease 
(CHD). This result was contrary both to prior observational studies and expert beliefs about 
biological pathways, and several hypotheses have been proposed to explain the study. In this 
paper, we examine if the results from WHI can be explained by differences in statin initiation 
between the randomization arms. Because of unmeasured confounding for the statin-CHD 
relationship, standard methods are unable to answer this question. We therefore provide a new 
g-estimation-based methodology for estimating the controlled direct effect, which relies on 
incorporating external information on the effect of the mediator. Specifically, we are able to 
provide a valid estimate for the direct effect of hormone replacement therapy on CHD, even in 
the presence of unmeasured confounding for the statin-CHD relationship. Despite substantial 
differences in LDL-cholesterol and statin initiation between the randomization arms, we find 
that statins had little impact on the results of the trial.  
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1.   Introduction: 
The Women’s Health Initiative (WHI) clinical trial randomized 16,608 women with intact uterus 
to either hormone replacement therapy (HRT) with conjugated equine estrogens and 
medroxyprogesterone acetate (E+P), or placebo. In July 2002, this trial was stopped early, after 
finding a 29% greater incidence of coronary heart disease (CHD) among women in the E+P 
hormone therapy arm.1 As data collection for the intervention phase became more complete, 
the HRs were 1.24 (95% CI: 1.00 – 1.54)2 and 1.18 (95% CI, 0.95-1.45)3 in updated analyses. 
 
Several hypotheses have been suggested to explain the findings from the WHI trial. Much 
interest has been on the timing of HRT initiation.4,5 An alternative hypothesis is that the results 
could be explained by differences in post-randomization initiation of HMG-CoA Reductase 
Inhibitors (statins). Hormone therapy is known to reduce serum levels of LDL cholesterol,6 and 
doctors are less likely to prescribe statins in patients with low LDL cholesterol. Statins are 
known to lower the risk of CHD.7 Women in the treatment arm of the WHI had lower post-
randomization levels of LDL than those in the placebo group, presumably due to the LDL-
lowering effect of oral estrogens; thus, they may have had a lower probability of initiating statin 
treatment. This could potentially explain the trial finding.  
 
If the results from the WHI trial are explained by differential statin usage, this would not mean 
that the trial was somehow less valid. Indeed, any effect of HRT, even if it is due to its effects 
on statin initiation, is part of the causal effect that a randomized trial is designed to estimate. 
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However, a natural interpretation of such a conclusion would be that HRT makes it more 
difficult to identify those women who would benefit from Statin treatment. This would suggest 
either that the prognostic value of LDL is reduced or that the LDL threshold value for statin 
initiation needs to be adjusted in women receiving HRT. Moreover, if the results from the trial 
are explained by differential statin initiation, this may go some way towards rehabilitating the 
observational studies that preceded WHI, which in most cases were conducted before statins 
became widely available and therefore would not be expected to capture the hypothetical 
component of the effect that is mediated by statins.  
 
To examine the hypothesis that the trial findings could be explained by differential use of 
statins, we estimated the direct effect of estrogen relative to statin usage. Because of 
unmeasured confounding for the statin-CHD relationship, the direct effect of estrogen is not 
identified from the WHI data alone. We therefore provide a new methodology based on 
incorporating external information about the effects of statins, which enables us to estimate the 
direct effect of estrogen even in the presence of mediator-outcome confounding. This external 
information was obtained from another large randomized trial, the Anglo-Scandinavian Cardiac 
Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA),8 which compared Atorvastatin to Placebo. 
We considered 3 outcomes: CHD (defined as acute myocardial infarction requiring overnight 
hospitalization, silent myocardial infarction identified through serial electrocardiograms, or 
death due to CHD), stroke, and all-cause mortality.  
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2.   Study Setting, Intermediate Biomarkers and Statin Usage: 
From 1993 to 1998, 16,608 women aged 50-79 were randomized to HRT with E+P or Placebo 
as part of the Women’s Health Initiative. Of the participants, 1,115 used statins at baseline and 
were excluded from our analysis, leaving us with a sample size of 15,493. Participants were 
followed from randomization until the event of interest, death, loss to follow-up or July 2002, 
whichever occurs first. As part of follow-up, participants completed annual questionnaires on 
changes to their medical history including initiation of statins; therefore, if a woman started 
statins in the same year she had a heart attack it is difficult to tell what happened first. Some 
covariates, including post-baseline serum lipids and cholesterol, were only collected in a 
random subsample (the Core Analytes), consisting of 6.6% of the study participants.  
 
Baseline characteristics of participants in the WHI trial are shown in Table 3.1. A summary of 
the key post-baseline biomarkers as measured in the Core Analytes subsample is shown in 
Table 3.2. On average, one year after baseline women in the E+P arm had 12.7 percentage 
points lower LDL-c (95% CI: 10.5%-14.6%), 7.3 percentage point higher HDL-c (95%CI: 5.5-
9.0%), and 5.4 percentage points lower total cholesterol (95% CI: 2.5% - 11.5%) than women in 
the placebo arm. Results at year 3 were nearly identical to those at year 1.9 These intermediate 
biomarkers suggest a substantial beneficial effect of HRT on lipid profiles.  
 
By the end of follow-up, 10.2% of the placebo arm and 15.9% of the HRT arm had initiated 
statin treatment. This implies a cumulative incidence difference for statin initiation of 5.7% (95% 
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CI: 4.6% - 6.8%). A Kaplan-Meier curve with statin initiation as the outcome is shown as figure 
3.1; this graph shows that throughout the course of the trial, women in the placebo arm were 
more likely to initiate statins than women in the E+P arm. The difference between the arms is 
highly unlikely to be due to sampling variability; one hypothesis to explain the graph is that 
doctors were less likely to prescribe statins to users of HRT because their lipid profiles were 
improved.  
 
These findings are all consistent with what one would expect to see if the effect of HRT is partly 
mediated by differential statin initiation, but there are multiple other explanations that are also 
consistent with the data. For example, statin initiation could be a marker for high cholesterol 
without being a significant mediator of the causal effect of HRT. The descriptive statistics alone 
are not sufficient to differentiate the statin hypothesis from other explanations, and we 
therefore turn to a formal mediation analysis in the next sections. In order to do so, we will 
incorporate external information on the causal effect of statins.  
 
Based on a meta-analysis by the Cholesterol Treatment Trialists’ Collaboration, we assumed 
the causal Hazard Ratio associated with statin usage was 0.70 for CHD, and that this hazard 
ratio was relatively homogenous between different subgroups.10 We assumed hazard ratios of 
0.76 and 0.91 for stroke and all-cause mortality, respectively.  
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For certain analyses, we were required to identify a trial on statin usage where the published 
results included separate Kaplan Meier curves for each outcome. Among trials that met this 
requirement was the ASCOT-LLA8, from which we extracted information about the effect of 
statins. Briefly, ASCOT-LLA was a multicenter randomized controlled trial which randomized 
10,305 hypertensive patients aged 40-79 years old to 10mg atorvastatin once daily, or 
placebo. This trial estimated that initiation of statin treatment was associated with an intention-
to-treat hazard ratio of 0.64 for non-fatal myocardial infarction and fatal CHD (95% CI: 0.50-
0.83). Adherence-adjusted effect estimates from ASCOT-LLA have not been published. A 
summary of baseline characteristics in this trial is shown in Table 3.3. Only 18.8% of participants 
were women, this represents a major difference between the ASCOT-LLA and WHI study 
populations; we were unable to find a statin trial that was limited to women.  
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Table 3.1: Characteristics of Participants in WHI E+P trial who did not take statins at baseline 
(n=15493) 
 
Variable E+P (n=7926) Placebo (n=7567) 
 Age 
Median 
Interquartile Range 
63 
57-69 
63 
58-69 
White 6659 (84.0%) 6659 (84.1%) 
BMI (kg/m2) 28.5 (5.8) 28.5 (5.9) 
Systolic blood pressure, 
mmHg 127.6 (17.6) 127.8 (17.5) 
Diastolic blood pressure, 
mmHg 75.6 (9.1) 75.8 (9.1) 
Current smoker 880 (10.5%) 838 (10.5%) 
Statins  
By end of follow-up 1188 (15.7%) 799 (10.1%) 
CHD 
Before baseline  
During follow-up 
 504 (6.9%) 
 165 (2.1%) 
520 (6.4%) 
125 (1.7%) 
Stroke  
Before baseline 
During follow-up 
54 (0.7%) 
132 (1.7%) 
66 (0.9%) 
96 (1.3%) 
Deaths 
 By end of follow-up  210 (2.6%) 203 (2.6%) 
 
Parenthesis are either percentages or standard deviations, depending on variable type. 
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Table 3.2: Laboratory results in Core Analytes subsample (N=1319) 
 
  
Mean at 
baseline 
(Pooled 
across 
randomization 
arms) 
SD 
Change 
Difference 
(Average 
percentage 
change in 
E-P arm, 
minus 
Average 
Percentage 
Change in 
Placebo 
arm) 
95% CI 
Total cholesterol 
(mg/dl) 
222 37.1  -5.4% -4.0%, -7.0% 
LDL-c (mg/dl) 134.7 32.9 -12.7% -10.5%, -14.5% 
HDL-c (mg/dl) 55.3 13.6 7.3%  5.5%, 9.0% 
Serum Triglycerides 
(mg/dl) 
130.9 59.4 -6.9% -2.5%, -11.5% 
 
Note: Direct access to data from the Core Analytes subsample was not obtained. Figures are 
from published results. For baseline measurements, the averages are pooled over 
randomization status.  
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Table 3.3: Baseline characteristics of participants in the ASCOT-LLA trial. Parenthesis are 
percentages or standard deviations, depending on variable type 
	  
 Atorvastatin (n=5168) Placebo (n=5137 
Women 979 (18.9%) 963 (18.7%) 
Age 
≤60 
>60 
 
1882 (36.4%) 
3286 (63.6%) 
 
1853 (36.1%) 
3284 (63.9%) 
White 4889 (94.9%) 4863 (94.7%) 
Total cholesterol (mg/dl) 212.7 (30.9) 212.7 (30.9) 
LDL-cholesterol (mg/dl) 131.5 (27.1) 131.5 (27.1)) 
HDL-cholesterol (mg/dl) 50.3 (15.5) 50.3(15.5) 
BMI (kg/m2) 28.6 (4.7) 28.7 (4.6) 
Systolic blood pressure, 
(mmHg) 
164.2 (17.7) 164.2 (18.0) 
Diastolic blood pressure, 
(mmHg) 
95.0 (10.3) 95.0 (10.3) 
Current smoker 1718 (33.2%) 1656% (32.2%) 
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Figure 3.1: Statin initiation over time in the WHI trial 
	  
	  3.   Standard Analysis  
Baron and Kenny (1986)11 described a method for estimation of the direct and mediated effects 
that has become widely utilized and cited. Briefly, they suggest using a series of regression 
models to check for mediation by assessing (1) whether the exposure is associated with the 
outcome, (2) whether exposure is associated with the suspected mediator and (3) whether the 
effect of the exposure is attenuated when conditioning on the mediator. In the WHI trial, this 
approach to mediation analysis is not valid; even if post-baseline cholesterol had been 
measured in all individuals the Baron-Kenny approach would have been invalid because LDL 
confounds the effect of statins but acts a mediator on the causal pathway from HRT to CHD.12  
 
In order to illustrate certain aspects of the data set, we conducted the analysis suggested by 
Baron-Kenny, both in the full WHI data set and in women not taking statins at baseline. Note 
that in the previous section, we have already determined that exposure to HRT causes 
increased incidence CHD, and that exposure to CHD causes reduced incidence of statin 
initiation, corresponding to the first two Baron-Kenny criteria for mediation. Regression 
parameters corresponding to the Baron-Kenny analysis are shown as Table 3.4. Survival curves 
predicted from the parameters of these models are shown as Figures 3.2-3.3.  
 
These models show that history of statin usage is highly correlated with CHD among women in 
WHI: When the statin variable is used as originally coded in the dataset, the hazard ratios 
associated with statin use exceed 2.5. This is almost certainly an artifact of the previously 
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mentioned data collecting process, which makes it hard to sort out the temporal sequence of 
events if statin initiation and CHD occur during the same year. It is therefore very likely that this 
correlation is driven in large parts reverse causation, ie that women are initiating statin 
treatment because they have been diagnosed with CHD.   For the remainder of our analyses, 
we therefore used a statin variable that was delayed by a year. Using this lagged version of the 
variable, the hazard ratio associated with statin usage remains above 1. Given that statins are 
known to be protective, this is a clear indication that women initiating statins are at higher risk 
than those who don’t, ie that the effect of statins is highly confounded.  
 
After we deleted women taking statins at baseline, the unadjusted hazard ratio for HRT in our 
data set is 1.24 (0.98-1.56). We note that the coefficients for the effect HRT are not attenuated 
by conditioning on statin initiation; in fact, the effect of HRT is if anything slightly amplified in 
three of the models after conditioning on statin initiation. This must be seen in light of the 
known confounding for the effect of the mediator. The Baron-Kenny analysis therefore does 
not allow us to conclude either way, and we turn to a different approach to mediation analysis 
in the next section. 
 
We also conducted an analysis in a dataset where people were censored at the time they 
initiated statin treatment. In this dataset, the Hazard Ratio associated with HRT was 1.28 (95% 
CI: 0.99 - 1.65) when using the original statin variable to determine censoring time, and 1.23 
(95% CI: 0.97 – 1.56) when using the delayed variable.  
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For reference, we also provide the incidence rates for CHD, both overall and during person 
time on statins: In women not taking statins at baseline, the incidence rate of CHD during WHI 
was 0.0033 per person year. In women who initiated statins during WHI (based on the 
unaltered variable), the incidence rate after initiation was 0.0081 per person year. If we delay 
the statin variable by a year, the incidence rate after statin initiation is 0.0038 per person year.  
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Table 3.4: Hazard Ratios associated with HRT and Statins in different pooled logistic models in 
the WHI data set 
 Outcome: 
CHD 
 
Predictors: 
HRT  
Outcome: 
CHD 
 
Predictors: 
Statins  
Outcome: 
Statins 
 
Predictors: 
HRT 
Outcome:  
CHD 
 
Predictors:  
HRT and Statins 
Outcome:  
CHD 
 
Predictors: 
HRT, Statins and Interaction 
Term 
HRT Statins HRT HRT Statins HRT Statins Interac
tion 
Term 
Full WHI 
dataset 
(n=16608) 
Untransformed 
Statin variable  
1.20 
(0.96- 
1.49) 
2.66  
(2.08- 
3.39) 
 
 
- 
1.24  
(1.01- 
1.55) 
 
    
2.69 
(2.1-
3.44)  
1.26  
(0.99-
1.64) 
2.77 
(1.90-
3.87) 
0.95 
(0.58-
1.55) 
Lagged Statin 
variable1 
1.20 
(0.96- 
1.49) 
1.90  
(1.43 - 
2.52)  
 
 
- 
1.22 
(0.98 
- 
1.45) 
    
 
1.92 
(1.41-
2.57) 
1.28  
(1.00-
1.62) 
2.15 
(1.41-
3.12) 
0.80  
(0.46-
1.40) 
WHI 
excluding 
those on 
statins at 
baseline  
(n = 15493) 
Untransformed 
Statin variable 
1.24  
(0.98- 
1.56 
2.69  
(1.93 - 
3.74) 
0.62 
(0.56 
-0.67) 
1.30 
(1.03 
- 
1.64) 
    
 
2.79 
(2.00-
3.88) 
1.26  
(0.99-
1.64) 
2.54 
(1.55-
3.95) 
1.21 
(0.64-
2.32) 
Lagged Statin 
variable 
1.24  
(0.98 
- 1.56 
1.11 
(0.65- 
1.92) 
0.61 
(0.55 
-0.68) 
 
 1.24  
(0.98- 
1.56) 
    
1.12  
(0.66-
1.98) 
1.26  
(1.00-
1.62) 
1.34  
(0.66-
2.58) 
0.68  
(0.22-
2.10) 
 
1The statin variable was lagged by 12 month in all individuals except those taking statins at 
baseline, in whom initiation was known to occur before month 1 such that reverse causation 
cannot occur 
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Figure 3.2: Survival curves predicted from standard models (with untransformed statin 
variable, model without interaction term)
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Figure 3.3: Survival curves predicted from standard models (without interaction terms, with 
lagged statin variable)  
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Figure 3.4: Kaplan Meier curves for WHI E+P trial (showing both original data, and data where 
women are censored at the time of statin initiation, delayed by 12 months) 
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4.   Identification of the Controlled Direct Effect 
Let T be the primary time scale of the WHI trial (time since randomization), and let K be a 
secondary time scale for time since initiation of statin therapy. Let A represent the baseline 
(intention-to-treat) treatment assignment with HRT and Mt be a time-varying indicator for 
whether the woman has initiated statin treatment by time T. The counterfactual survival time 
under estrogen treatment is labelled Ta=1, and the counterfactual survival time under no 
estrogen treatment is labelled Ta=0. The variable TA refers to the counterfactual survival time 
when evaluated at the treatment value for HRT that the woman received (ie the value that was 
randomly assigned); under the consistency condition TA is equal to the observed survival time 
T. TA,m=0 refers to a similar counterfactual survival time where the treatment value for hormone 
replacement therapy is evaluated at the observed value, and statins are not initiated.  
 
In the ASCOT-LLA trial, time since statin initiation is equal to time since randomization; the 
primary time scale of the ASCOT-LLA trial therefore corresponds to the secondary time scale K 
from the WHI trial. On the K time scale, the intention-to-treat indicator for statin initiation is 
time-fixed and we can therefore drop the time subscript (ie, Mk=M at all time points), otherwise 
all variables are identical between the trials. Km=0 and Km=1 are counterfactual variables for the 
survival times from statin initiation; sometimes we will be discussing the distribution of these 
survival times in terms of their equivalent causal survival functions under statin treatment and 
no statin treatment, S0(k) and S1(k) respectively. Let H(k)= S0-1(S1(k)) be the quantile-quantile 
function that describes the relationship between these two survival time distributions. This 
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function takes a time point k as input, finds the quantile of people in the statin arm who failed 
at that time, and gives as output the time point at which the corresponding quantile has the 
event under no statin treatment.  
 
Our aim is to estimate what the effect of HRT would have been in the WHI trial in the absence 
of post-randomization initiation of statin therapy, i.e., the “controlled direct effect”13 of 
hormone replacement therapy. In other words, we are interested in emulating a hypothetical 
“target trial” that is different from the one that was actually conducted, such that the protocol 
of the target trial specifies that participants cannot initiate statin treatment. This will require us 
to identify the counterfactual distribution of survival time under hormone replacement therapy 
and no statin treatment f(Ta=1,m=0), and the counterfactual distribution of survival time under no 
hormone replacement therapy and no statin treatment f(Ta=0,m=0), in terms of observed data.  
 
The target trial can be emulated using WHI data alone if one has measured all joint predictors 
of hormone replacement therapy and CHD, and all joint predictors of statin initiation and CHD. 
Randomization of treatment assignment ensures that there is no confounding of the intention-
to-treat effect of hormone replacement therapy. The primary confounders of the Statin-CHD 
relationship are the serum lipids and cholesterol measurements. Since these covariates were 
only measured in a subset of 6.6% of the WHI trial, the controlled direct effect is not identified 
from the WHI data, and methods such as marginal structural models cannot be used.  
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However, the controlled direct effect of hormone replacement therapy is identified from a 
combination of the WHI data and the ASCOT-LLA data under the following conditions:  
 
•   Ta, m=0 ∐ A for all values a (in the WHI trial), 
•   Km=0 ∐ M (in the ASCOT-LLA trial)  
•   Equal treatment effects for statins between the following three groups: 
o   Participants in the ASCOT-LLA trial 
o   Initiators of statins in the Estrogen arm of the WHI trial 
o   Initiators of statins in the Placebo arm of the WHI trial 
 
Conditions (1) and (2) are both expected to hold due to random treatment assignment in the 
respective trials. The viability of condition (3) will depend on the similarity of the two trial 
populations in terms of baseline effect modifiers, and on the similarity between the initiators of 
statins in the two arms of the WHI trial in terms of time-dependent effect modifiers. We discuss 
the plausibility of this condition in the appendix. We next provide an outline of how the target 
trial can be emulated under these three conditions.  
 
First, observe that because of randomized treatment assignment in the ASCOT-LLA trial 
(Condition (2)), H(k) is identified from the ASCOT-LLA data. Under an assumption of rank 
preservation, this will allow us to compute the counterfactual survival time under no statin 
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treatment for participants in the treatment arm of the ASCOT-LLA trial: For any individual who 
initiated statins and later had the event at time K, the survival time under no statin initiation is 
given by Km=0 = H(K).  
 
Our next step is to use this quantile-quantile function as a link between the WHI dataset and 
the ASCOT-LLA trial. Among women who initiate statin therapy during WHI, the counterfactual 
survival time TA,m=0 is by definition equal to NA + KA, m=0: In words, this says that the time they 
would have survived without the event under no statin treatment is equal to the time they 
initiated statins, plus the time they would have survived under no treatment. If the treatment 
effect is the same in all subgroups defined in condition (3), the quantile-quantile function can 
be applied to compute the counterfactual survival time under no statin treatment among 
women in the WHI trial who initiated statins: KA, m=0 = 𝐻 𝐾I . Therefore, we know that: 
TA,m=0 = JK	  +	  L MK 	  N>	  O*P*NQO	  RSTS	  NQN*NP*SU	  (VW	  SXYPZ	  *TSP*FSQ*	  S>>S[*O)\K	  N>	  O*P*NQO	  RSTS	  Q]*	  NQN*NP*SU	  (VW	  []QONO*SQ[W)  
 
In other words, when H(k) is known, we can apply the G-estimation blip-down function to 
remove the effect of statins from all women in the WHI data set. To do this, we will need two 
pieces of information: The woman’s time of statin initiation N (because NA=N under 
consistency) and her observed event time (because TA = T under consistency, and 𝐾I	  can be 
calculated as TA-NA). Note that TA,m=0 cannot be calculated in participants who are censored. In 
these women, we can get a lower bound on TA,m=0 by calculating what it would have been if 
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they failed immediately after they were censored; this therefore serves as their adjusted 
censoring time. We discuss bias due to censoring later in the paper. 
 
In the data set where we have removed the effect of statins, we will observe the distribution 
f(Ta=1,m=0|A=1) in the stratum where A=1, and f(Ta=0,m=0|A=0) in the stratum where A=0. Under 
our exchangeability Condition (1) these distributions are equal to f(Ta=1,m=0) and f(Ta=0,m=0) 
respectively. Therefore, the randomized trial that compares these two counterfactual 
distributions can be emulated using any comparison between the groups A=1 and A=0 in the 
modified data set. 
 
5.   Estimation of the Controlled Direct Effect 
We proceed to give the quantile-quantile function a parametric form by specifying a structural 
nested accelerated failure time model (SNAFTM) for the effect of statins. We specify the model 
H(k) = 𝑒	  _`∗> b 	  b4 dk , which can be equivalently stated as  
 
K0 = 𝑒	  _`∗c`∗> b 	  M4 dk 
 
In this model, effects are measured as the multiplicative expansion of survival time due to 
treatment. 𝛹b	  is a vector parameter for the time-dependent effect of statins, and f(k) is the 
functional form for the interaction with time (we used indicator variables for time units of length 
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6 months). Because of randomized assignment of treatment (Condition 2) , 𝛹b is identified from 
the ASCOT-LLA data. Since we did not have access to the raw ASCOT-LLA data set, the 
published Kaplan-Meier curves were used to estimate 𝛹b. The procedure is explained in the 
appendix.  
 
Turning to the WHI data, we then used the g-estimation step down procedure based on 𝛹b to 
create a modified data set where failure times and censoring times were changed to remove 
the effect of statins. In this data set, we conducted both a non-parametric analyses in the form 
of Kaplan Meier estimators of the survival function, and fit the pooled logistic regression model 𝑙𝑜𝑔𝑖𝑡	   Pr 𝑌* = 1|𝐴, 𝑌*A, = 0 = 𝛽4,* + 𝛽,𝐴	  . Since A was randomly assigned, the parameter 	  𝛽, 
this model can be interpreted as the parameter γ1 of the structural Cox model 𝜆P,FB4 𝑡 =𝜆],FB4 𝑡 ×𝑒fg×P, where 𝑒fg	  is the Hazard Ratio associated with the use of HRT when Statins are 
withheld. We also fit multivariate Cox models conditional on baseline covariates.  
 
Our approach takes the effect of statins to be fixed at the point estimate of ASCOT-LLA, such 
that our estimators do not incorporate uncertainty due to sampling variability in that trial. A 
sensitivity analysis was conducted to determine the extent to which our conclusions depend on 
the assumed value for the effect of statins. We did this by increasing and decreasing the values 
of each parameter for the effect of statins in increments of 50% of the observed value, ranging 
from 0% (ie, statins have no effect) through 100% (the observed effect of statins in the 
randomized trial) to 200% (double the effect seen in the trial).  
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6.   Administrative Censoring: 
Since the WHI trial was stopped in July 2002, all surviving individuals are administratively 
censored at that calendar date. The vast majority of censoring in WHI was administrative. A 
Kaplan Meier curve with censoring as the outcome is shown as Figure 3.5. On the time scale of 
the study, the time of administrative censoring is a variable: A woman who enrolled in 1995 will 
have at most 8 years of follow-up, whereas one who enrolled in 1998 will have at most 5 years 
of follow-up. Let the variable Ct indicate administrative censoring at time t, and Cta,m=0 be a 
counterfactual variable to denote whether the woman would have been administratively 
censored at time t when we intervene to prevent statin usage.    
 
If a woman is censored because of the end of the study (rather than being lost to follow-up), 
this is not expected to be correlated with cardiovascular risk unless one expects a secular trend 
in incidence. It is therefore commonly assumed that administrative censoring is non-
informative, a convention we will adopt by assuming Ct ∐ Ya, ie that the probability of being 
censored at any time t is independent of the cardiovascular risk. In our dataset, we tested the 
assumption of non-informative censoring by running an analysis where every individual is 
weighted by their probability of not being censored (estimated by a logistic model conditional 
on statin usage and baseline covariates).  When using stabilized weights, the weighted 
outcome model was identical to the unweighted model to three decimal places, providing 
some support for the assumption of non-informative censoring.  
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However, even if administrative censoring in the actual trial is non-informative, censoring in the 
emulated target trial may be informative because women taking statins have their censoring 
time accelerated. In other words, in the emulated trial, Cta,m=0 ∐ Ya, m=0 does not hold. Therefore, 
if doctors prescribed statins to women who were at higher cardiovascular risk, our procedure 
will lead to women at high risk being censored earlier than women at low risk.  
 
Structurally, the only cause of informative censoring in the emulated trial is the procedure we 
performed to accelerate failure times. Since this process depended only on the history of statin 
usage, we know that 𝐶*	  P,FB4	  ∐	  𝑌P,FB4	  |𝐴,𝑀* . We can therefore eliminate the bias by weighting 
all uncensored observations by 𝑤* = 	   ,lm[op	  q,rstB4	  |	  I,cp)	  * . Since the history of statin usage at 
time t can be summarized by an indicator for ever having initiated and the time since initiation 
(if they have initiated by time t) , these weights can be estimated by fitting the model 𝑙𝑜𝑔𝑖𝑡	   Pr[𝐶* = 0 |	  𝐴,𝑀*) = 𝛽4,* + 𝛽,𝐴 + 𝛽7 ∗ 𝐼	   𝑡 > 𝑁 +	  𝛽< ∗ 𝐼 𝑡 > 𝑁 ∗ (𝑡 − 𝑁) in the modified 
data set. 
 
Table 3.5 shows the parameter estimates from the model for the weight numerator. Tables 3.6 
and 3.7 show the distribution of stabilized and unstabilized weights at time 60, 72 and 84 
(along the transformed time scale), and at the last observation for any individual. Note that 
some of these weights are very large, potentially leading to unstable estimates. 
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Figure 3.5: Kaplan Meier curve for censoring  
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Table 3.5: Parameter estimates from weight models (Pooled logistic models, Odds ratios) 
	  
 R Ever use of statin 
(Lagged 
indicator) 
Time since 
initiation 
(lagged) 
Numerator 0.858 - - 
Denominator 0.896 2.898 1.022 
 
  
84	  
	  
Table 3.6: Distribution of stabilized weights over time 
	  
Time Observations  Mean  Median 90th 
Percentile 
99th 
Percentile 
Max 
observation 
60 10638 1.01  0.96 0.96 3.60 15.75 
72 5446 1.27 0.91 0.91 2.99 118.54 
84 2182 1.48 0.87 0.87 45.96 60.23 
At last 
observation 
15493 1.83 0.93 1.61 9.29 805.96 
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Table 3.7: Distribution of unstabilized weights over time 
 
Time Observations  Mean  Median 90th 
Percentile 
99th 
Percentile 
Max 
observation 
60 10638 1.47 1.36 1.41 5.10 23.63 
72 5446 3.48 2.29 2.52 8.73 345.94 
84 2182 12.30 6.10 7.47 322.67 577.50 
At last 
observation 
15493 10.17 1.84 12.22 80.18 8699.39 
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7.   Structural Nested Cumulative Failure Time Models 
Structural nested cumulative failure time models (SNCFTM) are an alternative to accelerated 
failure time models. These models are less sensitive to administrative censoring, but require a 
rare outcome assumption. In this section, we proceed to estimate the controlled direct effect of 
HRT using similar principles as above, but using a SNCFTM for the effect of statins in place of 
the SNAFTM. All variables are the same as in the previous section; in addition, we will further 
define the baseline covariates using the letter L. This is not because we are worried about 
confounding, but rather to discuss assumptions that have to be made about possible effect 
modification by L.  
 
Picciotto et al (2012)14 describe the general form of a SNCFTM. In our case, since we are using 
a time-fixed intention to treat variable for the effect of statins, we will be able simplify the 
models considerable from those considered by Picciotto. Let E 𝑌bz 𝐿,𝑀  be the average 
counterfactual risk of developing the outcome by Y time k, given the observed covariate and 
treatment history at the time of statin initiation, had everybody initiated treatment with statins. 
The general model for the intention-to-treat effect of statin initiation is then given by:  
 
𝑒f`({,c;	  }∗)	  = ~[`,|{,c]	  ~[`t|{,c]  
 
where 𝛾b 𝐿,𝑀; 	  𝜓 ∗ 	  is a function of treatment and covariate history indexed by the 
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(possibly vector-valued) parameter ψ whose unknown true value is ψ*. An immediate 
consequence of this model is that 𝐻b ψ ∗ = 	  𝑌b×	   ,S`(,;	  ∗) has the same conditional mean 
(given baseline covariates and treatment history) as the counterfactual probability of having the 
event by time k, ie E[𝑌bzB4|𝐿,𝑀]. Picciotto et al refer to 𝛾b 𝐿,𝑀; 	  𝜓 ∗  as the “blip down 
function” and provide several different variations of functional forms. If we assume 
~[`,|{,c]	  ~[`t|{,c] 	  is 
constant over time, 𝑒f`({,c;	  }∗) is then equal to the hazard ratio, which can be estimated either 
from a specific trial, or from a meta-analysis. If we further assume that the hazard ratio is 
constant between levels of baseline covariates L, we can use the simple model 𝑒f`({,c;	  }∗)	  = 
𝑒	  }×c.  
 
We next proceed to remove the effect of statins from the WHI data, by assuming that the blip-
down function 𝑒f`({,c;	  }∗)	  is equal between the following three groups: 
  (1) Women initiating statins in the HRT arm of WHI 
  (2) Women initiating statins in the Placebo arm of WHI  
  (3) Participants in the Statin trial  
 
For any possible time of statin initiation in WHI (denoted n), we define the subset of the study 
participants who are eligible to initiate statins, ie those who have not had the event and who 
have not already initiated statins prior to n. Consider their probability of having the event by 
time k (where k>n), under the intervention where statins are not initiated at any time point after 
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n, conditional on whether they initiated treatment. Mathematically, this is written as 
E[𝑌bI,F`B4|	  𝐿 = 𝑙, 𝑌Q = 0,𝑀QA, = 0,𝑀Q = 𝑚].  
 
For those women who initiated statins, we can blip down their observed data E[𝑌bI|𝐿 = 𝑙, 𝑌Q =0,𝑀QA, = 0,𝑀Q = 1] to the counterfactual mean E[𝑌b,zB4|𝐿 = 𝑙, 𝑌Q = 0, 	  𝑀QA, = 0,MQ = 1] by 
replacing the distribution of events at time k with 𝐻b 𝜓 ∗ .	  Among women who did not initiate 
statins, the observed data E 𝑌bI 𝐿 = 𝑙, 𝑌Q = 0,𝑀QA, = 0,𝑀Q = 0 	  is equal to the counterfactual 
mean	  E[𝑌b,zB4|𝐿 = 𝑙, , 𝑌Q = 0,𝑀QA, = 0,𝑀Q = 0] by consistency; therefore, the observed 
distribution does not need to be altered in these women.  
 
In most applications of g-estimation, it is necessary to implement the blip-down procedure 
sequentially, working backwards from the last possible time of treatment. However, in our 
specific case, because treatment can only be initiated once, any individual will at most be 
blipped down at one time point. Therefore, the analysis can be pooled it over time n.  
 
We implemented this analysis as follows: first we fit a pooled logistic model for the probability 
of CHD in individuals taking statins (ie where t>n). We then used this model to predict the 
instantaneous risk at all time points t, and multiplied this predicted risk by the reciprocal of the 
hazard ratio for statins. We next ran 10000 Monte Carlo simulations, where each individual had 
one Bernoulli trial at each time point, with the time-dependent failure probabilities were given 
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by the predicted risks. Follow-up ends at the time of the (simulated) event, or observed time of 
follow-up, whichever occurs first. The observed data was retained in individuals not taking 
statins. In each resulting data set we fit a Cox model with randomization arm as the predictor, 
averaging the parameter estimates over all simulations. 95% confidence intervals were 
obtained using a non-parametric bootstrap with 250 samples. 
 
8.   Results: 
We first replicated the results from the WHI trial by fitting an unadjusted Cox model, with the 
randomized treatment assignment as the only predictor. This model showed a Hazard Ratio of 
1.24 (95% CI: 0.98-1.56), corresponding to the published results  
 
Table 3.8 shows the estimated direct effects of estrogen on CHD and on the secondary 
outcomes (stroke and all-cause mortality). In the unweighted SNAFTM analysis, adjusting the 
survival times to remove the effect of statins resulted in a minor reduction in the hazard ratio, 
to 1.22 (95% CI: 0.96-1.54). Including the baseline covariates in the outcome model had 
negligible impact.  Note that when the weights are applied, the results change in 
unpredictable directions. This is likely due to a near-violation of positivity. In the case of the 
unstabilized weights, the change of the direction of the effect may be related to the fact that 
these weights, which do not use time in the numerator, giving more importance to the latter 
parts of the survival curve where HRT is protective.  In light of the surprisingly large differences 
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between different weighted analyses, we advise that the results from the SNAFTM analysis 
should be interpreted with caution. 
 
Figure 3.6 shows the unadjusted and adjusted Kaplan Meier curves for the analysis based on 
accelerated failure time models. In the SNCFTM analysis, the adjusted hazard ratio based on 
10000 Monte Carlo simulations was 1.22 (95% CI: 0.97-1.50). The adjusted Kaplan Meyer curve 
based on the SNCFTM model is shown as Figure 3.7.  
 
Tables 3.9 and 3.10 show sensitivity analysis where we varied the assumed effect of statins, to 
show how sensitive our estimates are to our assumption that we have reliable external 
information on the effect of statins. We note that both in the case of the SNCFTM and the 
unweighted SNAFTM,  even large changes to the assumed effect of statins lead to qualitatively 
similar effect estimates. 
 
Much of the impact of our adjustment is concentrated in the later years: When censoring all 
women at 5 years and 6 years, adjustment has negligible impact on the hazard ratio for CHD. 
Results at 5 years are shown as Table 3.11.  This is reflected in the survival curves, where the 
the adjusted survival curve is essentially superimposed on the unadjusted arm during the first 
years of the trial. 
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Because we sometimes cannot be sure that statin initiation happened before the heart attack 
(and because statin initiation sometimes happens because of a heart attack) we delayed the 
variable Mt by a year in the primary analysis. In a sensitivity analysis, we used the originally 
recorded time of statin initiation; this had negligible impact on the SNAFTM analysis. In the 
case of the SNCFTM analysis, this led to substantially increased risks in both arms of the study, 
but had little impact on the hazard ratio. It is not surprising that the SNCFTM analysis is more 
affected by using the original statin variable, as the parameter 	  𝛼7 in the model 𝑙𝑜𝑔𝑖𝑡	   Pr 𝑌*|𝑌*A, = 0, 𝐴,𝑀 = 𝛼4,* + 𝛼, ∗ 𝐴	  +	  𝛼7 ∗ I 	  𝑀* ≠ 0 ∗ +	  𝛼< ∗ I 	  𝑀* ≠ 0 ∗ (𝑡 − 𝑁) will be 
seriously affected by “reverse causation bias”, whereas no similar parameter for the effect of 
statins is estimated from the WHI data in the accelerated failure time model.  
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Table 3.8: Hazard Ratios for Secondary Outcomes 
	  
Outcome Unadjusted 
Hazard 
Ratio (in 
subset who 
did not 
take statins 
at 
baseline, 
n=15493) 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Unweighted 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted by 
stabilized 
weights 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted by 
stabilized 
weights 
truncated at 
40 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted by 
unstabilized 
weights 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted by 
unstabilized 
weights 
truncated at 
40 
Adjusted 
Hazard 
Ratio 
(SNCFTM) 
CVD 1.24  
(0.98- 
1.56) 
1.22  
(0.96- 
1.54)  
1.25 
(0.99- 
1.59) 
1.23 
(0.97-
1.56) 
0.95 
(0.75- 
1.21) 
0.96  
(0.70- 
1.35) 
1.22  
(0.97-
1.50) 
Stroke 1.33  
(1.03 – 
1.73) 
1.32 
(1.02- 
1.72) 
1.38 
(1.06- 
1.80) 
1.44  
(0.94- 
2.22) 
1.53 
(0.99- 
2.02) 
1.42  
(1.02- 
2.36) 
1.33  
(1.04-
1.66) 
All-
Cause 
Mortality 
0.98  
(0.82- 
1.18) 
0.98  
(0.81-
1.18) 
0.98 
(0.81-
1.18) 
0.98 
(0.81-
1.18) 
0.98 
(0.75- 
1.29) 
0.97 
(0.73- 
1.27) 
0.97  
( 0.81- 
1.14) 
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Table 3.9: Sensitivity Analysis for unweighted SNAFTM models 
 
Outcome Unadjusted 
analysis 
Adjusted to 
50% of 
statin effect 
in trial 
Adjusted to 
100% of 
statin effect 
in trial 
Adjusted to 
150% of 
statin effect 
in trial 
Adjusted to 
200% of 
statin effect 
in trial 
 CHD 1.24  
(0.98-1.56) 
1.22 
(0.97-1.55) 
1.22  
(0.96-1.54)  
1.21 
(0.96-1.53) 
1.21 
(0.96-1.53) 
Stroke 1.33  
(1.03 – 1.73) 
1.33 
(1.02-1.72) 
1.32 
(1.02-1.72) 
1.32 
(1.02-1.71) 
1.32 
(1.02-1.71) 
All Cause 
Mortality 
0.98  
(0.82-1.18) 
0.98  
(0.82-1.18) 
0.97 
(0.81-1.18) 
0.97  
(0.81-1.18) 
0.97  
(0.81-1.18) 
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Table 3.10: Sensitivity analysis for SNCFTM model 
	  
Outcome Unadjusted 
analysis 
Adjusted to 
HR=0.85 
Adjusted to 
HR=0.70 
(result from 
meta-
analysis) 
Adjusted to 
HR= 0.55 
Adjusted to 
HR=0.40 
CHD 1.24  
(0.98-1.56) 
1.23 
(0.94 -1.51 
1.22  
(0.97-1.50) 
1.21 
( 0.92-1.44) 
1.17 
(0.93--1.41) 
 
 
Outcome Unadjusted 
analysis 
Adjusted to 
HR=0.89 
Adjusted to 
HR=0.76 
(result from 
meta-
analysis) 
Adjusted to 
HR= 0.63 
Adjusted to 
HR=0.50 
Stroke 1.33  
(1.03 – 1.73) 
1.33 
(1.07 - 1.68) 
 
1.33  
(1.04-1.66) 
1.32 
(1.07-1.65) 
1.31 
(1.05 - 1.63) 
 
Outcome Unadjusted 
analysis 
Adjusted to 
HR=0.94 
 
 
Adjusted to 
HR=0.91 
(result from 
meta-
analysis) 
Adjusted to 
HR= 0.87 
Adjusted to 
HR=0.82 
All-Cause 
Mortality 
0.98  
(0.82-1.18) 
0.98  
(0.88 - 1.10) 
0.97  
(0.81- 1.14) 
0.97  
(0.88 - 1.11) 
0.97  
(0.87 -1.09) 
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Table 3.11: Adjusted hazard ratios at the end of year 5 
 
Outcome Unadjusted 
Hazard 
Ratio (in 
subset who 
did not 
take statins 
at 
baseline, 
n=15493 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Unweighted 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted 
by 
stabilized 
weights 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted 
by 
stabilized 
weights 
truncated 
at 40 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted 
by 
unstabilized 
weights 
Adjusted 
Hazard 
Ratio 
(SNAFTM) 
 
Weighted 
by 
unstabilized 
weights 
truncated 
at 40 
CVD 1.47  
(1.13-1.92) 
1.46 
(1.12-1.91) 
1.46 
(1.12-
1.91) 
1.46 
(1.12-
1.91) 
1.46 
(1.12-1.91) 
1.46 
(1.12-1.91) 
Stroke 1.41 (1.05, 
1.89) 
1.39 
(1.04-1.85) 
1.39 
(1.04-
1.85) 
1.37 
(1.03-
1.84) 
1.37 
(1.03-1.84) 
1.39 
(1.04-1.84) 
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Figure 3.6: Adjusted Kaplan-Meier curve from SNAFTM models (Unweighted) 
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Figure 3.7: Adjusted Kaplan Meier curve from SNCFTM model 
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9.   Discussion: 
We have provided a new method for determining whether the results of a randomized trial can 
be explained by post-baseline variation in a mediator variable. This method is valid regardless 
of whether there is unmeasured confounding of the mediator-outcome relationship as long as 
one has an unbiased external estimate of the effect of the mediator. We applied this new 
method to data from the WHI trial, to estimate the direct effect of HRT relative to statin 
initiation and thereby determine if the trial results could be explained by differences in statin 
usage between the randomization arms. This question is of interest not only for its clinical 
implications, but also as due to its implications for the interpretation of observational studies 
on HRT that preceded WHI.  
 
In the WHI trial, women in the E+P arm were less likely to initiate statins than women 
randomized to placebo. This is plausibly explained by differences in lipid profiles, as women in 
the estrogen arm have significantly lower LDL cholesterol. In other words, doctors appear to 
withhold statins in women taking estrogen because their cholesterol levels are lower. However, 
our analysis suggests that differential initiation of statins cannot explain the trial findings: The 
minor reductions in the hazard ratios are unlikely to be clinically relevant, and must be seen in 
light of the wide confidence intervals.  
 
This may seem counterintuitive in light of the substantial difference in utilization between the 
arms. In order to resolve this apparent paradox, we want to point out that most of the effect of 
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HRT in the WHI trial was seen during the first few years after baseline. During this time, few 
women had initiated statins in either arm of the study. This is reflected in our analysis by the 
finding that adjustment to remove the effect of statins had negligible impact during the first 
few years of follow-up.  
 
As any analysis, our study has limitations. Our approach takes the effect of statins as being 
fixed at the point estimate of the trial in which it was estimated, we therefore do not 
incorporate sampling variability from that trial. However, our sensitivity analysis show that 
varying the assumed effect of statins had relatively little impact on the conclusions. Moreover, a 
large number of randomized trials have been conducted on statins, with relatively consistent 
findings, which suggest that the effect of statins is known with at least some degree of 
certainty.   
 
A further limitation is that the SNAFTM blip-down procedure induces informative censoring in 
the resulting dataset, and the weights we estimated to adjust for this bias had inconsistent 
impact on the models, making it difficult to interpret the estimates.  However, it is reassuring 
that the SNCFTM model, which is not subject to the same type of informative censoring bias, 
had relatively similar results.    
 
The crucial assumption underlying this analysis is that the effect of statins is equal between 
initiators of statins in the WHI trial and the participants in the statin trial, on the effect measure 
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that was used to transport the effect. We note that meta-analyses of statin trials provide some 
evidence that the effect of statins is relatively constant between different subgroups on the 
hazard ratio scale. 
  
Despite the limitations of the study, it seems unlikely that any of them would have caused a 
bias that would substantially alter the interpretation of the results.  We conclude that at least in 
some subset of women, hormone replacement therapy with estrogen and progestin has a 
direct effect on coronary heart disease, which is not explained by failure to initiate statin 
treatment.   
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APPENDIX TO CHAPTER 1 
	  
	  
The need for inverse probability weights 
 
To see why inverse-probability weighting is required to adjust for previous findings at 
colonoscopy, consider the directed acyclic graph in Appendix Figure 1. At is an indicator for 
colonoscopy at time t, Lt is an indicator for the (possibly unknown to the investigator) presence 
of adenomas at time t, Lt* is an indicator for the presence of known adenomas at time t. 
Adenomas only become known through colonoscopy: If At=1 then Lt+1* = Lt, otherwise Lt+1* = 
Lt*. U represents the common causes of adenomas and colorectal cancer, such as genetics. Y is 
an indicator of colorectal cancer by the end of follow-up. 
 
According to this causal diagram, Lt+1* is a confounder for the effect of At+1 on Y: Knowledge of 
adenomas at time t+1 predicts colonoscopy at time t+1, and is also a marker for actual 
adenomas Lt, which cause cancer at time k>t. However, confounding adjustment via 
conditioning on the collider Lt+1* would open the biasing path Atà Lt+1*ßLt àY. Note that, to 
avoid clutter, we chose not to include the direct arrow from At-1 (not shown on graph) to Lt, 
which would only increase the number of biasing paths.  
 
Another possible problem is that conditioning on Lt+1* may partially block the effect of At 
through the path AtàLt+1*àY. The arrow Lt+1*àY exists because the detection of polyps 
necessarily leads to polypectomy, which affects the risk of cancer at later times.  
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Figure	  A.1:	  Causal	  directed	  acyclic	  graph	  to	  represent	  the	  effect	  of	  At	  (colonoscopy	  at	  time	  t	  followed	  by	  
polypectomy	  if	  necessary)	  on	  colorectal	  cancer	  Y.  
	  
	  
 
 
In this graph, Lt is an indicator for the presence of adenomas and Lt* is an indicator for the 
presence of known adenomas at time t. 
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APPENDIX TO CHAPTER 3 
 
On The Homogeneity of the Causal Effect 
The meta-analysis of Statin trials conducted by the Cholesterol Treatment Trialists collaboration 
(CTT)7 suggests that the effect of statins is relatively homogenous between different patient 
groups on the Hazard Ratio scale 7 . However, this is not sufficient to establish the validity of 
our analysis, which requires the effect to be homogenous on the accelerated failure time scale. 
We next proceed to discuss the conditions under which homogenous effects on the Hazard 
Ratio scale implies homogenous effects on the accelerated failure time scale.  
 
It is well established that if failure times follow an exponential or Weibull distribution, then the 
parameters of an accelerated failure time model will equal the parameters of a proportional 
hazards model1. Therefore, if one assumes an exponential distribution, homogenous hazard 
ratios on the hazard ratio scale will necessarily lead to homogenous parameters in the 
accelerated failure time model. However, since hazards tend to increase with age, exponential 
failure times is an assumption which is difficult to justify. We therefore conducted a simulation 
study to determine the extent to which the parameter of the an accelerated failure time model 
will be non-homogenous between different risk groups, if the effects are homogenous on a 
hazard ratio scale. 2 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Rosner B. Fundamentals of biostatistics. Boston: Brooks/Cole, Cengage Learning; 2011. 
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In the WHI data set, the observed rate of CHD was 0.0032 per person year. We created a 
simulated randomized trial comparing statin usage to no statin usage in two groups of people: 
A high risk group with a baseline rate of 0.004 events per person year, and a low risk group 
with 0.002 events per person year. In both groups, we assumed that CHD incidence rate 
increases by 5% every year from baseline. In both statin arms, all hazards were multiplied by a 
hazard ratio of 0.70.  
 
In this simulated data set, we then fit an accelerated failure time mode in each subgroup. 
These two accelerated failure time models had very similar parameters for the expansion of 
survival time, both slightly below 0.7. This is consistent with the conjecture that if the effects 
are homogenous on the hazard ratio scale, they will also be relatively homogenous on the 
accelerated failure time scale  
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Estimation of Ψb using published Kaplan Meier Curves 
 
The full specification of our model for the effect of statins is  
K0 = 𝑒	  _g∗c`∗ 4b +_∗c`∗ b,7 +	  _∗c`∗ ,7b, +⋯	  M4 dk 
Here, each Ψ parameter represents the contraction or expansion of survival time associated 
with statin treatment during a 6-month time interval since statin initiation.  
 
Using graphical software with a ruler and a rectangular drawing tool applied to the published 
Kaplan Meier curves, we mapped each time point in the Estrogen arm to the time point where 
the corresponding quantile in the Placebo arm failed. Our assumption of rank preservation 
gives us license to interpret this as the failure time that would have been observed under no 
treatment. 
 
For example, in order to estimate the parameter	  𝛹, , which is the effect during the first 6 
months, we begin by placing the corner of a rectangle on 6 months on the X-axis. We then 
draw a line segment perpendicular to the X-axis, and place the second corner of this rectangle 
where it intersects with the Kaplan Meier curve for the estrogen arm. We then draw another 
line segment parallel to the X-axis, and place the third corner at the point where it intersects 
with the Kaplan Meier curve for the Placebo arm. The fourth corner of this rectangle will be the 
failure time under no treatment.  
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If we imagine that the individual who failed at month 6 in the Statin arm was mapped to a 
counterfactual survival time under no treatment in month 3, we can now estimate the treatment 
effect 𝛹b	  during the first 6 months by solving the equation 3 = 𝑒	  _g	  𝑑𝑘4 . In this case, we will 
find that 𝛹, = 	  −0.69.	   
 
Knowing the value of 𝛹,	  , we can then go on to estimate 𝛹7. To do this, we repeat the process 
at the 1 year mark by solving K0 = 𝑒	  _g∗c`∗ 4b +_∗c`∗ b,7 	  ,74 for 𝛹7, where 𝛹,	  has been 
substituted by its estimate -0.69 
 
